{"meta":{"query_hash":"ed0f6a6f7fe7","filters":{"venue":"PharmacoEconomics - Open"},"cohort_total":81,"direct_labels_cover":0,"predictions_cover":81,"exported":81,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/ed0f6a6f7fe7","api":"https://metacan.xera.ac/api/v1/cohort?venue=PharmacoEconomics+-+Open"},"results":[{"id":"W2555011614","doi":"10.1007/s41669-016-0007-y","title":"Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicaid; Reimbursement; Quarter (Canadian coin); Medical prescription; Pharmacy; Medicine; Prescription drug; Population; Family medicine; Environmental health; Pharmacology; Health care; Geography; Economic growth; Economics","score_opus":0.10637381173363936,"score_gpt":0.42563498322346993,"score_spread":0.3192611714898306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555011614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872091,0.0003666049,0.0002210541,0.007574097,0.00029183718,0.0012669504,0.000028726616,0.000025182926,0.003016444],"genre_scores_gemma":[0.99520224,0.0013857917,0.00056975195,0.0016045377,0.00021321555,0.00009387265,0.000046249614,0.000028268443,0.000856065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988591,0.00003791297,0.0003363573,0.00035665513,0.00009563721,0.00031432847],"domain_scores_gemma":[0.9993418,0.000120600045,0.00012614702,0.00023231158,0.00003311211,0.00014604146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056362135,0.00015480074,0.00025856617,0.00011321769,0.00007176147,0.00011034662,0.0004818054,0.000055671386,0.00030434426],"category_scores_gemma":[0.000050901366,0.00010102108,0.00004614318,0.00012980883,0.00015317903,0.00022499776,0.00019420673,0.00009975476,0.000022706963],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013669035,0.0015068175,0.23003599,0.00019152598,0.00030488835,0.000075077834,0.012656139,0.000010195635,0.011099714,0.008978879,0.05337047,0.6804034],"study_design_scores_gemma":[0.009498189,0.00034553127,0.083106846,0.00012887405,0.00012763412,0.000075600794,0.000427882,0.0025135647,0.003824102,0.0002789221,0.89932615,0.000346707],"about_ca_topic_score_codex":0.000083390834,"about_ca_topic_score_gemma":0.000023324399,"teacher_disagreement_score":0.84595567,"about_ca_system_score_codex":0.000053934997,"about_ca_system_score_gemma":0.00004535963,"threshold_uncertainty_score":0.41195202},"labels":[],"label_agreement":null},{"id":"W2557026970","doi":"10.1007/s41669-016-0004-1","title":"Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Proxy (statistics); Reimbursement; Listing (finance); Drug prices; Economics; Product (mathematics); Actuarial science; Econometrics; Health care; Financial economics; Public economics; Finance; Computer science; Economic growth","score_opus":0.6938985898768593,"score_gpt":0.6033221729835111,"score_spread":0.09057641689334817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557026970","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000015211859,0.9024435,0.0006959042,0.018019022,0.002806335,0.015624538,0.013279626,0.000088679335,0.047040842],"genre_scores_gemma":[8.483931e-7,0.94264585,0.004903149,0.030859811,0.002528086,0.008443567,0.00051542633,0.0004063688,0.009696879],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98242086,0.00094580994,0.012439243,0.0026359167,0.00012612001,0.0014320549],"domain_scores_gemma":[0.9803051,0.0060462262,0.011026338,0.0017007431,0.00017749822,0.00074413046],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.036771864,0.0013326443,0.008144787,0.00060788053,0.0006387316,0.0008237963,0.0038610853,0.00057068974,0.051862914],"category_scores_gemma":[0.0022627371,0.00142324,0.0017176262,0.0001343845,0.00016067168,0.0021133563,0.0010133313,0.0006551335,0.036335375],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003139324,0.000091285445,0.00001671635,0.05204582,0.0012530881,0.0000011339263,0.0001272552,0.0000025806626,2.7381038e-8,0.007393341,0.7590834,0.17995398],"study_design_scores_gemma":[0.0017957211,0.00006484594,9.083403e-7,0.020952467,0.0006927479,0.00003087036,0.00001842253,0.0065536895,4.7260073e-7,0.0066328123,0.96167725,0.0015798],"about_ca_topic_score_codex":0.00022475954,"about_ca_topic_score_gemma":0.00003419469,"teacher_disagreement_score":0.20259386,"about_ca_system_score_codex":0.0038393238,"about_ca_system_score_gemma":0.002224306,"threshold_uncertainty_score":0.99998474},"labels":[],"label_agreement":null},{"id":"W2581612511","doi":"10.1007/s41669-017-0011-x","title":"Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Astellas Pharma Global Development; Astellas Pharma Europe; Astellas Pharma; Canadian Urological Association; Duchesnay; Pfizer","keywords":"Mirabegron; Tolterodine; Overactive bladder; Oxybutynin; Solifenacin; Medicine; Urology; Cohort; Internal medicine","score_opus":0.15893044462834857,"score_gpt":0.5192326041491452,"score_spread":0.3603021595207966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581612511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838906,0.00035362222,0.000003363732,0.0016252466,0.00021351952,0.002561723,0.00033023075,0.000001829116,0.011019877],"genre_scores_gemma":[0.99502724,0.0043047285,0.000047924215,0.00005944557,0.0001311744,0.00015438077,0.000028986637,0.00001819421,0.00022791204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999148,0.00004970907,0.00030515855,0.00020846118,0.000054365144,0.0002343085],"domain_scores_gemma":[0.9981166,0.00083657267,0.00026656015,0.0006849784,0.000038010072,0.00005727632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055980124,0.00014425642,0.00038307463,0.00005213814,0.00015947637,0.00009806072,0.0007539214,0.00003858863,0.00049941236],"category_scores_gemma":[0.000021420843,0.00008256004,0.00024302481,0.000015106206,0.00013404255,0.00023377687,0.00012935669,0.00010646685,0.000015237169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18061362,0.0071757715,0.3728373,0.00040179683,0.021069534,0.00008298884,0.030387897,0.008538761,0.00940303,0.0035330048,0.044404518,0.32155177],"study_design_scores_gemma":[0.10778997,0.02313493,0.6707538,0.000086023174,0.0018695813,0.000054509517,0.0026110031,0.05513667,0.05183415,0.0011494342,0.08481139,0.0007685757],"about_ca_topic_score_codex":0.0054530078,"about_ca_topic_score_gemma":0.0003134447,"teacher_disagreement_score":0.3207832,"about_ca_system_score_codex":0.00030240178,"about_ca_system_score_gemma":0.00049351004,"threshold_uncertainty_score":0.8243353},"labels":[],"label_agreement":null},{"id":"W2582749134","doi":"10.1007/s41669-017-0013-8","title":"Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”","year":2017,"lang":"en","type":"letter","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Economics; Financial economics; Econometrics","score_opus":0.2637735742554665,"score_gpt":0.4504590824979789,"score_spread":0.1866855082425124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582749134","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014014487,0.007678807,0.00024617385,0.7512441,0.004983571,0.007687798,0.01687709,0.00008906204,0.21105324],"genre_scores_gemma":[0.00015457995,0.011419762,0.003919112,0.9297816,0.010145806,0.0033274437,0.0008378994,0.0004945185,0.039919272],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913251,0.00013251527,0.0034639628,0.003030748,0.00009898108,0.0019487021],"domain_scores_gemma":[0.99233425,0.00083032803,0.0032825377,0.0024814147,0.00017893978,0.0008925604],"candidate_categories":["metaepi_narrow","scholarly_communication","open_science","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0057557034,0.0013530039,0.0030898578,0.0005963811,0.0009839743,0.0024970884,0.00638297,0.0007919878,0.03591286],"category_scores_gemma":[0.0006540652,0.0017029052,0.0011231482,0.00008537941,0.00020984227,0.0015733296,0.0020678814,0.00222808,0.01922839],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015476585,0.000070443144,0.00010556683,0.001308234,0.00091706065,0.000020441872,0.00018622915,0.00003853922,0.0000036917227,0.002026306,0.9912963,0.0038724472],"study_design_scores_gemma":[0.0022878007,0.00011180994,0.000019973984,0.00050445035,0.00035908702,0.00003181251,0.00000423991,0.036800876,0.00007249031,0.017555745,0.9402961,0.001955602],"about_ca_topic_score_codex":0.00084521656,"about_ca_topic_score_gemma":0.00002675344,"teacher_disagreement_score":0.17853749,"about_ca_system_score_codex":0.0015619231,"about_ca_system_score_gemma":0.0006866279,"threshold_uncertainty_score":0.9999221},"labels":[],"label_agreement":null},{"id":"W2601604409","doi":"10.1007/s41669-017-0018-3","title":"Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; St. Michael's Hospital","funders":"","keywords":"Consistency (knowledge bases); Activity-based costing; Drug pricing; Medicine; Political science; Actuarial science; Business; Accounting; Computer science","score_opus":0.7627049803111466,"score_gpt":0.6465122802148523,"score_spread":0.11619270009629434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601604409","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03994649,0.0114649255,0.00017921181,0.8765264,0.0026399149,0.006362735,0.0009866722,0.000038879585,0.061854776],"genre_scores_gemma":[0.47145176,0.04123893,0.015439087,0.45386422,0.0026591932,0.005503545,0.00029111904,0.00023391964,0.009318239],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9909664,0.0018724295,0.0049028858,0.0012401567,0.00006752857,0.0009506467],"domain_scores_gemma":[0.9920203,0.0022032636,0.0030083824,0.0020192838,0.000072830306,0.0006759147],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.06092061,0.0003992948,0.0021780636,0.00044703428,0.0011521787,0.0008677223,0.004409099,0.00018724136,0.006213479],"category_scores_gemma":[0.007163201,0.00043306153,0.00022959676,0.00011279936,0.00016390484,0.001498842,0.0008275709,0.0005242923,0.024588529],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050907413,0.00011863038,0.0209063,0.00024937055,0.00019828304,0.00000848036,0.0017277852,0.00083145074,0.000004631608,0.06842145,0.8982769,0.009205768],"study_design_scores_gemma":[0.0012424818,0.00004914645,0.026704064,0.00020296658,0.000029957377,0.000011975724,0.00023433518,0.004777331,0.00001843604,0.013796732,0.9523559,0.00057663163],"about_ca_topic_score_codex":0.2136718,"about_ca_topic_score_gemma":0.24663341,"teacher_disagreement_score":0.43150526,"about_ca_system_score_codex":0.0036924828,"about_ca_system_score_gemma":0.0014553315,"threshold_uncertainty_score":0.9998121},"labels":[],"label_agreement":null},{"id":"W2609661473","doi":"10.1007/s41669-017-0022-7","title":"Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Toronto Public Health; Public Health Ontario; University of Toronto","funders":"Canadian Institutes of Health Research; Tufts Medical Center","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.6709276885782226,"score_gpt":0.5865158343262132,"score_spread":0.08441185425200937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609661473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663998,0.00036374785,0.00046025685,0.010724726,0.002529069,0.0061677955,0.006853427,0.000027832362,0.00647338],"genre_scores_gemma":[0.99026394,0.000125798,0.001021111,0.0038878932,0.00038895578,0.0037023092,0.00047502908,0.000046083034,0.00008887508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99536246,0.00052955275,0.002753424,0.00084519206,0.000036289464,0.00047310628],"domain_scores_gemma":[0.9920932,0.0041040373,0.0027561658,0.0007688984,0.000047909394,0.00022978458],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009297839,0.00029202588,0.0015430063,0.00022407951,0.000924045,0.00073336856,0.0013244674,0.0001827945,0.0012008616],"category_scores_gemma":[0.0013061411,0.0004022754,0.00013875944,0.000039438408,0.00015976292,0.0020110146,0.00046019323,0.00024855774,0.00072954054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004946636,0.0017579639,0.72910464,0.00068301964,0.0017111785,0.00025745493,0.0060533965,0.00048792912,0.00016695156,0.1987511,0.049621224,0.006458524],"study_design_scores_gemma":[0.13512667,0.0016897199,0.29846624,0.0005808519,0.00026122722,0.00019067244,0.011511096,0.13624445,0.0015501922,0.15512142,0.25459084,0.004666625],"about_ca_topic_score_codex":0.023246022,"about_ca_topic_score_gemma":0.013965788,"teacher_disagreement_score":0.43063837,"about_ca_system_score_codex":0.0018698783,"about_ca_system_score_gemma":0.00031182572,"threshold_uncertainty_score":0.9998429},"labels":[],"label_agreement":null},{"id":"W2617296499","doi":"10.1007/s41669-017-0030-7","title":"Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Programs for Assessment of Technology in Health Research Institute; Impact","funders":"","keywords":"Bevacizumab; Ovarian cancer; Medicine; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.10839309429298337,"score_gpt":0.43427039666966477,"score_spread":0.3258773023766814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617296499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988376,0.00084802957,0.000001439477,0.0026416194,0.00060937845,0.003107551,0.0015783127,0.0000018305777,0.0028358002],"genre_scores_gemma":[0.9973195,0.0010061942,0.00023608649,0.000057715122,0.0000991513,0.0011443036,0.000059100224,0.000020645048,0.00005726535],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998836,0.00003039003,0.0005429609,0.00031254638,0.0000925074,0.00018559664],"domain_scores_gemma":[0.9986935,0.00007441921,0.00059061515,0.00045965565,0.000086212975,0.000095554096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000354205,0.00016071087,0.0006103609,0.000056225523,0.00007263136,0.000034118628,0.0002596756,0.000028898346,0.00089482556],"category_scores_gemma":[0.000015742922,0.00015051581,0.00007628076,0.000012734359,0.000026541653,0.00014980067,0.00006115,0.000025416406,0.0000023060813],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.006421968,0.0012299465,0.23459576,0.00025770685,0.002055895,0.000010135122,0.0006650558,0.007985532,0.0014195711,0.0012792323,0.0033503894,0.7407288],"study_design_scores_gemma":[0.09535861,0.0017322632,0.68840504,0.00049998023,0.0028179768,0.0000047103767,0.00024453385,0.07582735,0.105901726,0.000807295,0.02782882,0.0005716948],"about_ca_topic_score_codex":0.8744409,"about_ca_topic_score_gemma":0.9341331,"teacher_disagreement_score":0.7401571,"about_ca_system_score_codex":0.0061898576,"about_ca_system_score_gemma":0.005767173,"threshold_uncertainty_score":0.9998692},"labels":[],"label_agreement":null},{"id":"W2744741417","doi":"10.1007/s41669-017-0049-9","title":"Direct Mapping of the QLQ-C30 to EQ-5D Preferences: A Comparison of Regression Methods","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Statistics; Logistic regression; Ordinary least squares; Regression diagnostic; Regression analysis; Segmented regression; Censored regression model; Regression; Mathematics; Econometrics; Local regression; Cross-sectional regression; Linear regression; Polynomial regression","score_opus":0.8025354787775343,"score_gpt":0.6055012823377216,"score_spread":0.19703419643981268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744741417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85729325,0.0014317499,0.0041505713,0.02696128,0.0032074293,0.003673757,0.0008267472,0.00003283369,0.10242239],"genre_scores_gemma":[0.97032654,0.00013290152,0.024521867,0.0034681237,0.00020261208,0.00018586697,0.0000105251065,0.00004511041,0.0011064399],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937305,0.0006020821,0.0044562384,0.0006876214,0.000074954885,0.0004486283],"domain_scores_gemma":[0.9896879,0.000989362,0.007296662,0.0016836172,0.000093401984,0.00024905158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.020398833,0.00026520572,0.001882443,0.0002308772,0.00055049156,0.0002808962,0.003410844,0.00012768297,0.00068666076],"category_scores_gemma":[0.003082034,0.00026036432,0.00022969568,0.00010805828,0.00016104814,0.00091390806,0.0013720396,0.00022863444,0.00032882794],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003142349,0.00076914544,0.7599544,0.001637826,0.00096666696,5.3516067e-7,0.021358918,0.0031871551,0.0025110387,0.0553338,0.13038397,0.023582315],"study_design_scores_gemma":[0.0056577604,0.00028394212,0.2632221,0.0015799423,0.0001084582,0.000004430518,0.004153287,0.047554933,0.04222999,0.032883514,0.6004518,0.0018698283],"about_ca_topic_score_codex":0.0037574884,"about_ca_topic_score_gemma":0.00026211923,"teacher_disagreement_score":0.4967323,"about_ca_system_score_codex":0.00037315264,"about_ca_system_score_gemma":0.00026585988,"threshold_uncertainty_score":0.99998486},"labels":[],"label_agreement":null},{"id":"W2748882349","doi":"10.1007/s41669-017-0053-0","title":"Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact","funders":"","keywords":"Medicine; Confidence interval; Health care; Pharmaceutical care; Pulmonary tuberculosis; Public health; Retrospective cohort study; Tuberculosis; Family medicine; Emergency medicine; Internal medicine; Nursing; Pharmacy","score_opus":0.13414114809899066,"score_gpt":0.4376703003657257,"score_spread":0.30352915226673505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748882349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736924,0.0007801624,3.8873023e-7,0.017057132,0.00005027774,0.00090314605,0.00008919879,0.000009616225,0.0074176434],"genre_scores_gemma":[0.9952199,0.0016885614,0.00008033055,0.0019257845,0.00006412006,0.00009977818,0.000071178925,0.000022930091,0.0008274595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987905,0.00016909411,0.0003054849,0.00033785234,0.00005605718,0.00034101182],"domain_scores_gemma":[0.9988048,0.00030947602,0.00022378725,0.00038369803,0.000032610296,0.00024559547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005511048,0.00015905239,0.0006251745,0.0000814704,0.00015456493,0.00006546089,0.0002876809,0.00007027605,0.0001068399],"category_scores_gemma":[0.0002137963,0.000119877805,0.000039541494,0.00001873471,0.00015411769,0.00021816671,0.00024104187,0.00015600536,0.000010816308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019137367,0.0002812134,0.9809246,0.000043812932,0.00026492644,0.00014030194,0.0004987085,0.000008338731,0.0006385832,0.00003909908,0.0036745253,0.01157212],"study_design_scores_gemma":[0.00959442,0.0013470999,0.92992866,0.00027837345,0.00011203125,0.000058948826,0.0005443408,0.0015623597,0.0041045127,0.00020086662,0.051955353,0.0003130151],"about_ca_topic_score_codex":0.005974341,"about_ca_topic_score_gemma":0.003456407,"teacher_disagreement_score":0.050995957,"about_ca_system_score_codex":0.00018379842,"about_ca_system_score_gemma":0.0001741259,"threshold_uncertainty_score":0.9031457},"labels":[],"label_agreement":null},{"id":"W2752473968","doi":"10.1007/s41669-017-0051-2","title":"The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; Cancer Care Ontario; University of Manitoba; Western University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Retrospective cohort study; Cancer; Confidence interval; Propensity score matching; Internal medicine; Cohort; Primary tumor; Proportional hazards model; Cancer registry; Population; Oncology; Clinical trial; Surgery; Metastasis","score_opus":0.039770071195847176,"score_gpt":0.4071142063706688,"score_spread":0.3673441351748216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752473968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944242,0.000315065,0.000005762677,0.0012739064,0.0004087349,0.003104213,0.00013465506,0.000005229831,0.00032819924],"genre_scores_gemma":[0.9979695,0.0010626524,0.0001335803,0.00014856226,0.00008354813,0.0004547634,0.000055259974,0.000024982288,0.00006714822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981377,0.00013232969,0.001032941,0.0004345669,0.00010674633,0.00015568381],"domain_scores_gemma":[0.99814725,0.00017642885,0.0010259058,0.00049720035,0.00006651103,0.00008669286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001599228,0.0001631957,0.0008404999,0.00006982629,0.00016571945,0.00013099507,0.00037133635,0.000031153806,0.00006750933],"category_scores_gemma":[0.00003873636,0.0001365721,0.00011701006,0.000025543079,0.00014571381,0.0002619546,0.00021447234,0.00014280225,0.000004397995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008171581,0.0007728583,0.99365664,0.0000601115,0.00057671603,0.0000055609794,0.00008386934,0.0005027341,0.00057609624,0.00014012179,0.00015791856,0.0026502358],"study_design_scores_gemma":[0.007514337,0.00016056083,0.9861963,0.00005404663,0.0007443528,0.0000020593936,0.000059444577,0.0033754378,0.0014947773,0.00025206766,0.000032881675,0.00011374238],"about_ca_topic_score_codex":0.020219259,"about_ca_topic_score_gemma":0.0029903653,"teacher_disagreement_score":0.017228894,"about_ca_system_score_codex":0.00072111114,"about_ca_system_score_gemma":0.00052765873,"threshold_uncertainty_score":0.9863052},"labels":[],"label_agreement":null},{"id":"W2755337532","doi":"10.1007/s41669-017-0057-9","title":"Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact","funders":"","keywords":"Medicine; Health care; Pharmacist; Tuberculosis; Indirect costs; Family medicine; Pulmonary tuberculosis; Total cost; Emergency medicine; Pharmacy","score_opus":0.10154513704508793,"score_gpt":0.41883768569945967,"score_spread":0.31729254865437173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755337532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905235,0.0008766065,5.698078e-7,0.0031755317,0.00010113951,0.0011438141,0.00026187795,0.0000042571196,0.0039127106],"genre_scores_gemma":[0.99786955,0.0011285422,0.00012993286,0.00062803196,0.000022482393,0.0000338092,0.00013593081,0.000019124285,0.0000326031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979518,0.00029364036,0.0010099408,0.00032581226,0.000119305136,0.00029948115],"domain_scores_gemma":[0.9979747,0.00025621612,0.0009323938,0.00047299245,0.000066274886,0.0002974286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001997037,0.00015942333,0.0012253189,0.00014581904,0.000072294,0.000016562964,0.00042553715,0.00009297905,0.00017787449],"category_scores_gemma":[0.00029900883,0.00013056136,0.00006124434,0.00003011143,0.00024045986,0.00027151534,0.00038023107,0.00025228542,0.000003780216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028819675,0.0004307928,0.98531044,0.00026305366,0.0003328498,0.0000032143173,0.00025572628,0.000008179083,0.00038528309,0.000036727826,0.002310918,0.0077808667],"study_design_scores_gemma":[0.005650313,0.00030107982,0.9915842,0.00012183701,0.000028672419,0.000001572016,0.00006177594,0.0001760315,0.0014106124,0.00008113211,0.0004661834,0.00011662508],"about_ca_topic_score_codex":0.013890103,"about_ca_topic_score_gemma":0.0012600278,"teacher_disagreement_score":0.012630076,"about_ca_system_score_codex":0.00010277812,"about_ca_system_score_gemma":0.00024528173,"threshold_uncertainty_score":0.9926765},"labels":[],"label_agreement":null},{"id":"W2765486768","doi":"10.1007/s41669-018-0088-x","title":"International HTA Experience with Targeted Therapy Approvals for Lung Cancer","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Griffith University; Cardiff University","keywords":"Lung cancer; Medicine; Targeted therapy; Intensive care medicine; Oncology; Medical physics; Cancer; Internal medicine","score_opus":0.4290643303047238,"score_gpt":0.5516916771965357,"score_spread":0.12262734689181187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765486768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81361985,0.0031635384,0.02549847,0.085311905,0.0071440646,0.009104151,0.0031494473,0.00017881517,0.052829772],"genre_scores_gemma":[0.8837015,0.0016343149,0.024768813,0.07395793,0.0041397484,0.0063295974,0.00023269509,0.00020068535,0.005034691],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99606943,0.00009316563,0.002336143,0.00092562527,0.000060481594,0.000515135],"domain_scores_gemma":[0.9969326,0.00035790654,0.001812489,0.0005039915,0.00016872936,0.00022428324],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0054167057,0.00028381066,0.0008345814,0.00021001838,0.00034626471,0.000469711,0.0015300801,0.0000949749,0.0058092275],"category_scores_gemma":[0.0002498898,0.0003267913,0.00010595916,0.00011536742,0.0001572425,0.001603834,0.00020160574,0.00012985984,0.00044795228],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021728643,0.00069681474,0.20781174,0.000326725,0.002364792,0.0000021968779,0.024725651,0.0015424003,0.0005821655,0.11868342,0.6334589,0.0076322914],"study_design_scores_gemma":[0.005311803,0.00015241043,0.0030480889,0.00004719803,0.00001282732,0.000004758221,0.000681839,0.09314895,0.0014442834,0.0022266195,0.89316446,0.00075677014],"about_ca_topic_score_codex":0.0016458653,"about_ca_topic_score_gemma":0.00015946492,"teacher_disagreement_score":0.2597055,"about_ca_system_score_codex":0.0006802252,"about_ca_system_score_gemma":0.0002712079,"threshold_uncertainty_score":0.9999184},"labels":[],"label_agreement":null},{"id":"W2766103705","doi":"10.1007/s41669-018-0112-1","title":"Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McGill University","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Pembrolizumab; Regimen; Internal medicine; Oncology; Progression-free survival; Cost effectiveness; Immunotherapy; Cancer; Chemotherapy","score_opus":0.023948478740535926,"score_gpt":0.33105219360357485,"score_spread":0.30710371486303895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766103705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992232,0.00012205694,0.0000022201446,0.0004613411,0.00035433134,0.0049003726,0.00013984775,0.0000039327165,0.0017838452],"genre_scores_gemma":[0.99851674,0.0001506462,0.00008926621,0.0002595723,0.000018077499,0.00035429015,0.00034662028,0.000024318888,0.0002404659],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990692,0.000026815213,0.00037602553,0.00026885959,0.0000979092,0.00016120287],"domain_scores_gemma":[0.9993241,0.0000711914,0.00024956313,0.00020711376,0.000096364536,0.000051695115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026627435,0.0001444538,0.0003724592,0.00007040766,0.000030218018,0.000016196384,0.00014667217,0.000027203163,0.00075009995],"category_scores_gemma":[0.000005731268,0.00013226268,0.00004619176,0.000038096372,0.000013507747,0.0002279716,0.000027708746,0.000036802823,0.00001283041],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09628028,0.0015450829,0.4573766,0.00025982744,0.0015391335,0.0000020946711,0.0007920453,0.039757762,0.00092539954,0.00018909926,0.0010570636,0.40027562],"study_design_scores_gemma":[0.47663832,0.009059108,0.2624628,0.0002862927,0.0007046829,0.000006469616,0.00048236066,0.19699495,0.02438547,0.00028584414,0.02788225,0.0008114814],"about_ca_topic_score_codex":0.44759476,"about_ca_topic_score_gemma":0.6351725,"teacher_disagreement_score":0.39946416,"about_ca_system_score_codex":0.006962179,"about_ca_system_score_gemma":0.0030710015,"threshold_uncertainty_score":0.9968499},"labels":[],"label_agreement":null},{"id":"W2766253633","doi":"10.1007/s41669-017-0061-0","title":"The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian VIGOUR Centre; Institute of Health Economics; Alberta Hospital Edmonton; University of Alberta Hospital; University of Alberta","funders":"","keywords":"Medicine; Health care; Ambulatory care; Ambulatory; Emergency medicine; Acute care; Myocardial infarction; Population; Liberian dollar; Total cost; Medical emergency; Inpatient care; Environmental health; Business; Finance; Internal medicine","score_opus":0.04275009629830681,"score_gpt":0.397792840425913,"score_spread":0.35504274412760617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766253633","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38839558,0.00017615617,0.000005853377,0.55038786,0.0024391175,0.004521715,0.0003006973,0.000012971301,0.053760048],"genre_scores_gemma":[0.9887329,0.0015223015,0.000040159503,0.00646887,0.00040947885,0.00019307401,0.000047775156,0.000030728745,0.0025547629],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985774,0.00009585947,0.00046147394,0.00028658417,0.0001900554,0.0003886369],"domain_scores_gemma":[0.99833184,0.00019466574,0.00029047384,0.00079053093,0.00014997573,0.00024248779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007354251,0.00014700582,0.00042005384,0.000064955326,0.0004966758,0.00020823565,0.0010050626,0.000065353706,0.00013011481],"category_scores_gemma":[0.00011809611,0.00012515832,0.00010884381,0.000053805954,0.00015439451,0.00033650966,0.0006521767,0.0004132142,0.000042893575],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006163085,0.00014720269,0.1581082,0.00015096008,0.0064815427,0.00014353517,0.0013173667,0.00086927664,0.003487968,0.0041928273,0.6808234,0.13811466],"study_design_scores_gemma":[0.003860963,0.0000812532,0.054724935,0.00003380742,0.00013939098,0.000041947787,0.0002066209,0.0029379874,0.0022065481,0.00013327524,0.93543965,0.00019360908],"about_ca_topic_score_codex":0.9724072,"about_ca_topic_score_gemma":0.63111085,"teacher_disagreement_score":0.60033727,"about_ca_system_score_codex":0.00071296905,"about_ca_system_score_gemma":0.001982124,"threshold_uncertainty_score":0.5103808},"labels":[],"label_agreement":null},{"id":"W2801866300","doi":"10.1007/s41669-018-0083-2","title":"Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; International Collaboration On Repair Discoveries; Simon Fraser University; Vancouver Coastal Health","funders":"National Institute for Health and Care Research; Ontario Stroke Network; SFU Community Trust Endowment Fund; Health Technology Assessment Programme; Simon Fraser University; Tavistock Trust for Aphasia; EuroQol Research Foundation; Research for Patient Benefit Programme; Ontario Ministry of Health and Long-Term Care","keywords":"Valuation (finance); Preference; Process (computing); Quality of life (healthcare); Psychology; Conceptual framework; Quality (philosophy); Applied psychology; Computer science; Medicine; Nursing; Business; Sociology; Social science","score_opus":0.6861002413643779,"score_gpt":0.5569994370974879,"score_spread":0.12910080426688997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801866300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783393,0.0011151565,0.000083391315,0.013983657,0.0021634507,0.003327107,0.0005637795,0.0000060622074,0.00041806584],"genre_scores_gemma":[0.99555564,0.00034335436,0.0015092278,0.0019471223,0.00012217337,0.00031227915,0.00014217108,0.000028696079,0.00003932555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9891554,0.00093459705,0.00888639,0.00055693235,0.00009601797,0.00037066764],"domain_scores_gemma":[0.9873623,0.0028581657,0.008865564,0.0004957195,0.00029793175,0.00012031874],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.038404264,0.00022394715,0.0021751814,0.00039713434,0.0002444065,0.000042399988,0.0007167494,0.00008867691,0.00021138604],"category_scores_gemma":[0.0037159494,0.0002468076,0.00008772109,0.00023405654,0.00032276005,0.00069180306,0.00041224307,0.0001423034,0.000008785657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004695238,0.0002913108,0.52330446,0.0040503205,0.004028706,0.0000010783414,0.015914038,0.0056868377,0.000035941448,0.40771824,0.032967113,0.0013066876],"study_design_scores_gemma":[0.16861056,0.001454909,0.31769392,0.002453128,0.000528384,0.000051597697,0.042898264,0.21376944,0.0023469066,0.16826102,0.07797147,0.0039603747],"about_ca_topic_score_codex":0.831916,"about_ca_topic_score_gemma":0.30021474,"teacher_disagreement_score":0.5317012,"about_ca_system_score_codex":0.0024392984,"about_ca_system_score_gemma":0.007165517,"threshold_uncertainty_score":0.9999984},"labels":[],"label_agreement":null},{"id":"W2887988025","doi":"10.1007/s41669-018-0089-9","title":"Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs","keywords":"Paliperidone Palmitate; Medicaid; Paliperidone; Schizophrenia (object-oriented programming); Medicine; Pharmacy; Medical costs; Health care; Emergency medicine; Demography; Psychiatry; Family medicine; Antipsychotic; Political science","score_opus":0.058909682300852355,"score_gpt":0.3706249907799557,"score_spread":0.31171530847910334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887988025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796109,0.0012706137,0.000048543243,0.014427068,0.000099732875,0.001974628,0.00041665533,0.000049280305,0.002102555],"genre_scores_gemma":[0.9901778,0.00052149384,0.0054258048,0.0026864542,0.00028975029,0.00030957596,0.00044142883,0.000053037824,0.00009461462],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99785787,0.0001325284,0.000490419,0.0007419183,0.00024927652,0.00052796694],"domain_scores_gemma":[0.9984402,0.00017461771,0.000120552104,0.00037051435,0.00015557,0.0007385339],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039464558,0.00030879368,0.00059051503,0.00020544165,0.00028822618,0.00024054798,0.00033621496,0.00008999998,0.00039759485],"category_scores_gemma":[0.000056371096,0.00027386815,0.000040299386,0.00030712664,0.00019138803,0.00039482422,0.00019356069,0.0003021562,0.0000892397],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1998152,0.0011895858,0.13326026,0.00019005773,0.0014126629,0.00076121686,0.014114677,0.00036596047,0.0012273166,0.0040885285,0.008807637,0.6347669],"study_design_scores_gemma":[0.15456197,0.014294868,0.6333399,0.0055940324,0.0009701544,0.00020960145,0.009376934,0.024775406,0.03800554,0.004832389,0.11064483,0.0033943937],"about_ca_topic_score_codex":0.008898764,"about_ca_topic_score_gemma":0.05173347,"teacher_disagreement_score":0.6313725,"about_ca_system_score_codex":0.0003822001,"about_ca_system_score_gemma":0.0006897708,"threshold_uncertainty_score":0.99997133},"labels":[],"label_agreement":null},{"id":"W2890017653","doi":"10.1007/s41669-018-0092-1","title":"The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Spinal cord compression; Medicine; Compression (physics); Spinal cord; Psychology; Psychiatry; Materials science","score_opus":0.5773868384838766,"score_gpt":0.5226113793229547,"score_spread":0.05477545916092197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890017653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94298315,0.0066410783,0.0058066733,0.021627434,0.0032963324,0.009459429,0.0009002182,0.00010408655,0.009181622],"genre_scores_gemma":[0.97872084,0.0003644121,0.010947774,0.006021758,0.00052135345,0.0010979639,0.000026752788,0.00009922184,0.0021999078],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931924,0.00046665757,0.004664404,0.0008745054,0.00009309636,0.00070893805],"domain_scores_gemma":[0.99394596,0.0010742898,0.0035940069,0.00091082836,0.00021971505,0.00025519083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.018306829,0.00036683708,0.0015249605,0.0003594663,0.0010381148,0.0010196504,0.0029916044,0.0000851846,0.00032367563],"category_scores_gemma":[0.0012569855,0.00035482814,0.0002149906,0.00026933503,0.00030758386,0.0016406886,0.0009757758,0.0001961227,0.00055042625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021162821,0.0037858319,0.043088157,0.00804038,0.0061385776,0.000002205448,0.019358726,0.00076680805,0.0008494737,0.43604255,0.39115545,0.06960903],"study_design_scores_gemma":[0.00822707,0.001996592,0.00394137,0.00039960342,0.00011573287,0.000022907174,0.0036996347,0.12797336,0.002498523,0.021663593,0.82824475,0.0012168793],"about_ca_topic_score_codex":0.0012048756,"about_ca_topic_score_gemma":0.0001126468,"teacher_disagreement_score":0.4370893,"about_ca_system_score_codex":0.0004748903,"about_ca_system_score_gemma":0.00033632622,"threshold_uncertainty_score":0.9998904},"labels":[],"label_agreement":null},{"id":"W2925255986","doi":"10.1007/s41669-019-0153-0","title":"All-Male Panels and Gender Diversity of Issue Panels and Plenary Sessions at ISPOR Europe","year":2019,"lang":"en","type":"letter","venue":"PharmacoEconomics - Open","topic":"Diversity and Career in Medicine","field":"Social Sciences","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Diversity (politics); Plenary session; Political science; Engineering ethics; Library science; Engineering; Computer science; Law","score_opus":0.13582559758370824,"score_gpt":0.36840176837394856,"score_spread":0.23257617079024032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925255986","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25083718,0.00075897627,0.000005714117,0.49953976,0.0031883477,0.0023212968,0.0019433683,0.000054010234,0.24135135],"genre_scores_gemma":[0.044842362,0.0114962505,0.00010561243,0.8263053,0.0026774828,0.000011688999,0.00040595373,0.000056128625,0.11409918],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981491,0.0002783005,0.000272029,0.0005743758,0.00031599347,0.00041021383],"domain_scores_gemma":[0.9988026,0.0003328501,0.0003093816,0.00027351687,0.000092014336,0.0001896423],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011091164,0.00025701182,0.0005888494,0.00009886,0.0006983821,0.00016955743,0.0015374824,0.00032691666,0.0060316687],"category_scores_gemma":[0.000038326478,0.0002688613,0.00007150673,0.00006966365,0.0005330959,0.0005234924,0.005293726,0.00063380203,0.00025787784],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050124912,0.000022564687,0.009545402,0.00016822995,0.00022279407,0.000113574126,0.012140198,0.0000026904324,0.00004791158,0.00006316577,0.9766651,0.000958255],"study_design_scores_gemma":[0.0008979665,0.000029563527,0.0010459769,0.000038957558,0.00034252345,0.0000090112735,0.002183615,0.000015456293,0.000066110726,0.00015296343,0.99488497,0.00033286377],"about_ca_topic_score_codex":0.003901136,"about_ca_topic_score_gemma":0.00004908509,"teacher_disagreement_score":0.32676557,"about_ca_system_score_codex":0.0001277883,"about_ca_system_score_gemma":0.00017929928,"threshold_uncertainty_score":0.99997634},"labels":[],"label_agreement":null},{"id":"W2933306415","doi":"10.1007/s41669-019-0131-6","title":"Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Dulaglutide; Semaglutide; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Endocrinology; Exenatide; Liraglutide","score_opus":0.04761554358127133,"score_gpt":0.33630039552377733,"score_spread":0.288684851942506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933306415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848267,0.00040018235,1.7906572e-7,0.00048479292,0.00053571747,0.0035860194,0.00005169331,0.000005126071,0.010109579],"genre_scores_gemma":[0.998567,0.00039814741,0.000060265967,0.00024239022,0.000027470769,0.000210202,0.000083858424,0.000025138446,0.00038552214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985499,0.00016906505,0.0004585477,0.0003332014,0.00013145203,0.00035786378],"domain_scores_gemma":[0.9986256,0.0006414104,0.0001907397,0.00042578334,0.000039941533,0.00007654055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004997685,0.00023670113,0.0007645194,0.00012645744,0.000019076082,0.000020671192,0.00041615678,0.000033968307,0.00019579739],"category_scores_gemma":[0.000016781793,0.00018428282,0.00008244944,0.00021696257,0.000041337356,0.00013421457,0.000109286215,0.00008901675,0.000037153004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003993364,0.0018290867,0.9604909,0.0004431704,0.0010069987,0.000048338767,0.0006910863,0.003424759,0.002665512,0.000408862,0.00097349787,0.024024451],"study_design_scores_gemma":[0.06983942,0.005240975,0.7620916,0.00069528614,0.00097111106,0.0000017561716,0.0020639012,0.009664017,0.09033593,0.00015031324,0.058222957,0.0007227757],"about_ca_topic_score_codex":0.38022348,"about_ca_topic_score_gemma":0.25352907,"teacher_disagreement_score":0.1983993,"about_ca_system_score_codex":0.0020471294,"about_ca_system_score_gemma":0.0009412865,"threshold_uncertainty_score":0.7600921},"labels":[],"label_agreement":null},{"id":"W2935761670","doi":"10.1007/s41669-019-0132-5","title":"Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Akebia Therapeutics; Otsuka Pharmaceutical","keywords":"Medicine; Observational study; Quality of life (healthcare); Cochrane Library; Randomized controlled trial; Intensive care medicine; Kidney disease; Population; MEDLINE; Dialysis; Pediatrics; Internal medicine; Environmental health","score_opus":0.1412128731212003,"score_gpt":0.4430817841296246,"score_spread":0.30186891100842433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935761670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005556876,0.9678339,2.8423474e-7,0.00044103732,0.00012791052,0.024939315,0.00093055674,0.00001655209,0.00015360505],"genre_scores_gemma":[0.001605026,0.9934144,0.000039176884,0.000399081,0.000027188597,0.0018805442,0.0023433222,0.000104976076,0.0001862629],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9955735,0.00045114043,0.0026301602,0.00082043477,0.00014843393,0.00037629667],"domain_scores_gemma":[0.99510086,0.0004440417,0.0035191514,0.0006121116,0.00007254643,0.00025126993],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013867043,0.0006978892,0.008289521,0.00020484765,0.00005715475,0.00004587169,0.0003361188,0.00014360191,0.000061105115],"category_scores_gemma":[0.0000804324,0.00045608074,0.00037880475,0.0001262305,0.000054251752,0.00012140377,0.00011478655,0.00030374693,0.00004155105],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006839195,0.0009356232,0.0031390507,0.9217989,0.008251034,0.000002284921,0.00010865522,0.000009432485,1.0961841e-8,0.00003939772,0.0005435456,0.06448817],"study_design_scores_gemma":[0.02873776,0.0023251502,0.0012261725,0.9338089,0.022318548,0.0000039842907,0.000023418937,0.0000509915,6.500941e-7,0.0000044989843,0.0106617855,0.00083812885],"about_ca_topic_score_codex":0.00049783324,"about_ca_topic_score_gemma":0.00006616203,"teacher_disagreement_score":0.06365004,"about_ca_system_score_codex":0.0021174187,"about_ca_system_score_gemma":0.0012697078,"threshold_uncertainty_score":0.9997891},"labels":[],"label_agreement":null},{"id":"W2942619274","doi":"10.1007/s41669-019-0142-3","title":"A Systematic Review of the Health Economics of Pompe Disease","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Audentes Therapeutics","keywords":"Medicine; Enzyme replacement therapy; Life expectancy; Disease; Quality of life (healthcare); Quality-adjusted life year; Health economics; MEDLINE; Health care; Economic evaluation; Systematic review; Indirect costs; Pediatrics; Cost effectiveness; Family medicine; Physical therapy; Environmental health; Public health; Internal medicine; Nursing; Pathology","score_opus":0.12459082680849154,"score_gpt":0.47341610194434597,"score_spread":0.34882527513585443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942619274","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011190585,0.9759646,9.629126e-7,0.0009964597,0.00030077394,0.02010996,0.0006477578,0.0000074645354,0.0019608135],"genre_scores_gemma":[0.000009493649,0.99513227,0.000035439873,0.0025642898,0.000055983914,0.0005423839,0.00016560064,0.000107383,0.0013871319],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99566746,0.00061157026,0.0026326377,0.000535064,0.0001822611,0.00037099895],"domain_scores_gemma":[0.9945017,0.00031137266,0.0029615352,0.0017286475,0.00013275036,0.0003640107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018576608,0.00044626533,0.0068120826,0.00015757125,0.00005345846,0.0000399411,0.0023483788,0.00009493908,0.00052918727],"category_scores_gemma":[0.0003416276,0.00029722878,0.001391803,0.00023758838,0.00011152214,0.0001483235,0.0012934608,0.00046141163,0.00023718682],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003623637,0.0001398572,0.000007758559,0.97419554,0.0009182022,0.0000016507139,0.000018972754,9.4538075e-7,5.493927e-8,0.00024966395,0.003163831,0.021267315],"study_design_scores_gemma":[0.00058470055,0.00005518653,0.000001654288,0.64979094,0.0035255973,0.000022166596,0.000007909193,0.000046428417,0.00000100124,0.000016904614,0.34575453,0.0001929719],"about_ca_topic_score_codex":0.00016978457,"about_ca_topic_score_gemma":0.000005726499,"teacher_disagreement_score":0.34259072,"about_ca_system_score_codex":0.0007197185,"about_ca_system_score_gemma":0.0060142083,"threshold_uncertainty_score":0.99994797},"labels":[],"label_agreement":null},{"id":"W2943596749","doi":"10.1007/s41669-019-0137-0","title":"The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"University of Alberta; Alberta Health Services","keywords":"Clinical trial; Business; Medical device; Medicine; Internal medicine; Biomedical engineering","score_opus":0.6781917796155964,"score_gpt":0.6814709660396648,"score_spread":0.0032791864240684365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943596749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9202396,0.0006055543,0.0000023244747,0.038863618,0.0042689326,0.0030141808,0.00013881724,0.000025185454,0.03284177],"genre_scores_gemma":[0.97196186,0.002425372,0.00003184487,0.021434898,0.00058371277,0.00018533839,0.000034905122,0.00004573734,0.003296317],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9832,0.01111859,0.0037182013,0.00072721223,0.0002653746,0.00097059325],"domain_scores_gemma":[0.9685838,0.02852979,0.0010425841,0.0005435747,0.00013127507,0.0011689307],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.05100384,0.00037446048,0.0015798836,0.00012802896,0.00026103438,0.00010372604,0.002823148,0.002003976,0.01529902],"category_scores_gemma":[0.0058064274,0.0002985302,0.0003302094,0.00033956085,0.00047446165,0.00040884755,0.0009898702,0.0069433297,0.0011746855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0135493055,0.0019840994,0.61761963,0.00019530521,0.0014187259,0.00008757983,0.00057425926,0.00065133214,0.0018270832,0.048253242,0.06930953,0.24452989],"study_design_scores_gemma":[0.013519411,0.00020169336,0.007432912,0.00011953976,0.00020941091,0.000032827647,0.00036027536,0.023549091,0.008426536,0.0010329378,0.94456154,0.00055384426],"about_ca_topic_score_codex":0.0014086214,"about_ca_topic_score_gemma":0.0014444656,"teacher_disagreement_score":0.875252,"about_ca_system_score_codex":0.00025720577,"about_ca_system_score_gemma":0.0013831719,"threshold_uncertainty_score":0.99994665},"labels":[],"label_agreement":null},{"id":"W2943673305","doi":"10.1007/s41669-019-0139-y","title":"A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Impact; Programs for Assessment of Technology in Health Research Institute","funders":"Mitacs","keywords":"Agency (philosophy); Population; Health care; Business; Family medicine; Medicine; Public health; Cost–benefit analysis; Private sector; Actuarial science; Accounting; Environmental health; Political science; Nursing","score_opus":0.6885709978218029,"score_gpt":0.6102526625261878,"score_spread":0.07831833529561505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943673305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015285322,0.92130095,0.00006510639,0.06433647,0.00078962446,0.006404794,0.0036135132,0.000027310478,0.0033093863],"genre_scores_gemma":[0.0014489554,0.982523,0.00031776627,0.012416855,0.0002444224,0.00066946505,0.0020331144,0.00011365458,0.00023277171],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98604697,0.0014295564,0.010016871,0.0013947763,0.0001461976,0.00096563564],"domain_scores_gemma":[0.98468584,0.0025169884,0.010155594,0.0014362171,0.00017170554,0.0010336757],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.024649967,0.0008391678,0.009238577,0.0015937245,0.0005555193,0.00053551554,0.002668281,0.0003528004,0.0052111563],"category_scores_gemma":[0.0015383199,0.0007436908,0.0009779441,0.0012908912,0.00034896343,0.0010608447,0.00060856185,0.0010009859,0.0010243049],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040457362,0.00047647965,0.04516364,0.082966276,0.027982637,0.0000035928765,0.0016601422,0.00012403364,1.8359174e-7,0.025995664,0.615389,0.20019789],"study_design_scores_gemma":[0.00078349136,0.00006229652,0.0004554339,0.0036380521,0.0032638223,0.00000667069,0.00010701854,0.0038789364,1.3700134e-7,0.00019120224,0.9869004,0.0007125601],"about_ca_topic_score_codex":0.09076011,"about_ca_topic_score_gemma":0.036361836,"teacher_disagreement_score":0.37151137,"about_ca_system_score_codex":0.0024437974,"about_ca_system_score_gemma":0.0016849336,"threshold_uncertainty_score":0.99975353},"labels":[],"label_agreement":null},{"id":"W2952476208","doi":"10.1007/s41669-019-0143-2","title":"The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Bruyère; University of Ottawa","funders":"Canadian Institutes of Health Research; University of Ottawa","keywords":"Retrospective cohort study; Medicine; Environmental health; Cohort; Population; Population health; Database; Family medicine; Business; Computer science","score_opus":0.1620565774407131,"score_gpt":0.43403084027377725,"score_spread":0.27197426283306414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952476208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879091,0.00010278417,0.000024443967,0.0017720758,0.00068340055,0.008577214,0.00014332481,0.000011478881,0.00077621423],"genre_scores_gemma":[0.99748796,0.00002060838,0.00031863162,0.0017805642,0.000031020747,0.00006546444,0.00015944686,0.00002608242,0.000110234505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741334,0.00043873192,0.0010078176,0.000466024,0.0002890972,0.00038497365],"domain_scores_gemma":[0.9979204,0.00033677442,0.0009569637,0.00042095286,0.00010063086,0.00026425964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019595837,0.00021489794,0.0008262833,0.00006711441,0.0002121667,0.00007976806,0.0003461344,0.000020576113,0.000120509765],"category_scores_gemma":[0.000061444785,0.00017605521,0.000055318094,0.0001215013,0.000023913772,0.0003449714,0.00019989072,0.00048662146,0.0000036405534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001605274,0.00033999464,0.9958871,0.00011495029,0.00023846542,0.000009784802,0.0003009472,0.0007496702,0.000015279897,0.00030140107,0.00017006253,0.0002670603],"study_design_scores_gemma":[0.00538355,0.0005589245,0.9612184,0.00025130663,0.000105544204,0.000008050783,0.0015607233,0.029290766,0.00005131757,0.000004078643,0.0013754138,0.00019189707],"about_ca_topic_score_codex":0.9925568,"about_ca_topic_score_gemma":0.9823747,"teacher_disagreement_score":0.034668684,"about_ca_system_score_codex":0.0071487254,"about_ca_system_score_gemma":0.008276101,"threshold_uncertainty_score":0.99734604},"labels":[],"label_agreement":null},{"id":"W2954548710","doi":"10.1007/s41669-019-0156-x","title":"The Use of Computer Simulation Modeling to Estimate Complications in Patients with Type 2 Diabetes Mellitus: Comparative Validation of the Cornerstone Diabetes Simulation Model","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Medicine; Diabetes mellitus; Absolute risk reduction; United Kingdom Prospective Diabetes Study; Type 2 diabetes; Clinical trial; Confidence interval; Internal medicine","score_opus":0.0777691001279494,"score_gpt":0.3536708675563976,"score_spread":0.2759017674284482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954548710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913978,0.000044826065,0.0053065163,0.00009982482,0.00011202082,0.002928424,0.00004049704,0.000010157962,0.000059933867],"genre_scores_gemma":[0.9967971,0.0000070192755,0.0027707426,0.00021268571,0.000018604978,0.000043029228,0.00011005051,0.000023324492,0.00001747761],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99882406,0.00009727629,0.00047179166,0.0002564521,0.0001659458,0.00018445025],"domain_scores_gemma":[0.9985448,0.0002868647,0.00026294365,0.0004914944,0.00035566738,0.000058195426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003572777,0.0001504174,0.0004543145,0.00007833785,0.00008409789,0.000068936126,0.00028070758,0.000038274706,0.000008705424],"category_scores_gemma":[0.000029413286,0.00010380989,0.00008537834,0.00019176793,0.00005327855,0.0004193496,0.00016959179,0.00011361885,0.000014021415],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018575667,0.00011567364,0.06913169,0.00003341163,0.00017602803,9.161171e-9,0.0003480924,0.9248178,0.0001105415,0.000035947294,0.000018505292,0.0050265375],"study_design_scores_gemma":[0.0018076763,0.00010856809,0.06467211,0.00010868009,0.00011917756,1.4392904e-8,0.0000125758515,0.93052197,0.002287555,0.00006945718,0.00017656245,0.000115680996],"about_ca_topic_score_codex":0.00020636189,"about_ca_topic_score_gemma":0.000037901507,"teacher_disagreement_score":0.0057041347,"about_ca_system_score_codex":0.00009693914,"about_ca_system_score_gemma":0.00007148593,"threshold_uncertainty_score":0.42332447},"labels":[],"label_agreement":null},{"id":"W2956056819","doi":"10.1007/s41669-019-0154-z","title":"US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Treatment of Major Depression","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Major depressive disorder; Medicine; Depression (economics); Retrospective cohort study; Cohort; Treatment-resistant depression; Internal medicine; Confidence interval; Propensity score matching; Comorbidity; Rate ratio; Psychiatry; Mood","score_opus":0.01090551635820826,"score_gpt":0.30067986308468414,"score_spread":0.2897743467264759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956056819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807875,0.00010303324,0.0000034309683,0.000097388875,0.00030969232,0.0074502416,0.00018505176,0.000055639564,0.01100801],"genre_scores_gemma":[0.9978755,0.00009056742,0.00017003622,0.00011524998,0.00011251185,0.00031010888,0.00017200026,0.00009484677,0.0010591528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779356,0.00011923611,0.0005272482,0.0010185929,0.00018534619,0.00035603432],"domain_scores_gemma":[0.9981935,0.00011317403,0.00048369728,0.00079887104,0.00019137698,0.00021937396],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002060098,0.00048669998,0.0011166827,0.00018127542,0.00009724307,0.00008948417,0.00041866984,0.00010369137,0.0014139175],"category_scores_gemma":[0.000008701259,0.00035557334,0.00014429391,0.00009567503,0.000060053415,0.00041790493,0.0002514557,0.00025954223,0.00023145319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016643526,0.0024026867,0.9721169,0.000009755929,0.002105326,0.000026372916,0.00073946355,0.0044219065,0.00016731698,0.000033011485,0.00033289858,0.0010008249],"study_design_scores_gemma":[0.028889475,0.0055658566,0.95625496,0.00014777319,0.00093483506,0.000004044604,0.0015944431,0.0037186106,0.0020750018,0.000020601887,0.00039258314,0.00040180696],"about_ca_topic_score_codex":0.0067775003,"about_ca_topic_score_gemma":0.00021974392,"teacher_disagreement_score":0.017088015,"about_ca_system_score_codex":0.0034665507,"about_ca_system_score_gemma":0.0002638922,"threshold_uncertainty_score":0.9998896},"labels":[],"label_agreement":null},{"id":"W2962517794","doi":"10.1007/s41669-019-0161-0","title":"The Costs of Industry-Sponsored Drug Trials in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Innovative Medicines Canada","keywords":"Cancer drugs; Medicine; Clinical trial; Drug; Business; Pharmacology; Internal medicine","score_opus":0.44391710692776887,"score_gpt":0.573564349915947,"score_spread":0.1296472429881781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962517794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9576337,0.0008137799,5.120239e-7,0.0148329465,0.0031940718,0.0025824045,0.0004433602,0.000015649757,0.020483583],"genre_scores_gemma":[0.9855712,0.00096914335,0.000019115354,0.010356728,0.00019982865,0.00016923217,0.00002831474,0.000034491473,0.00265197],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933887,0.0033377914,0.001780876,0.00047908473,0.00015787929,0.0008556595],"domain_scores_gemma":[0.99211556,0.0060899355,0.00072547636,0.00041330187,0.00010065997,0.0005550468],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011013808,0.00031894125,0.0010665582,0.0000905127,0.0002540902,0.00007879686,0.0018915465,0.0004440875,0.00670497],"category_scores_gemma":[0.00046423523,0.00026588474,0.00013484785,0.0002603037,0.00014525861,0.00033552042,0.00054623105,0.0035169816,0.00021616249],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011849601,0.0006963131,0.5651241,0.00027141502,0.0012869436,0.00011251973,0.0010398892,0.010927401,0.01632272,0.025742969,0.24061722,0.12600893],"study_design_scores_gemma":[0.009190374,0.000057547866,0.007377818,0.00006204447,0.00016410797,0.00001576048,0.0017288129,0.012101955,0.08049966,0.00081855344,0.8873693,0.0006141205],"about_ca_topic_score_codex":0.45672315,"about_ca_topic_score_gemma":0.4831818,"teacher_disagreement_score":0.64675206,"about_ca_system_score_codex":0.0013173552,"about_ca_system_score_gemma":0.0037066278,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W2965330563","doi":"10.1007/s41669-019-0159-7","title":"Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Salmonella and Campylobacter epidemiology","field":"Agricultural and Biological Sciences","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Typhoid fever; Widal test; Test (biology); Economic evaluation; Medicine; Decision tree; Computer science; Salmonella typhi; Artificial intelligence","score_opus":0.058734378705583644,"score_gpt":0.3704102202133898,"score_spread":0.3116758415078062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965330563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98780036,0.000022752154,0.0000014043214,0.0061165225,0.00044129626,0.003779248,0.00023733467,0.0000093632525,0.0015917156],"genre_scores_gemma":[0.99444366,0.000021798469,0.000024490817,0.0046286257,0.00024207914,0.00027178336,0.0000697739,0.0000031328855,0.00029467363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985592,0.00016899765,0.00047040783,0.0004272067,0.000061852545,0.00031233198],"domain_scores_gemma":[0.99781793,0.0016142039,0.00022197791,0.00013302224,0.000045253077,0.00016760326],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015976798,0.00016904695,0.00040185245,0.000028982,0.00006233958,0.00012534331,0.0009548222,0.00006850374,0.0014582934],"category_scores_gemma":[0.00022843815,0.000081386126,0.00006680028,0.00014397004,0.000022526589,0.00030490116,0.00045250737,0.0001347264,0.0010483958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002532719,0.00012913809,0.6599322,0.0000071521667,0.000041325016,9.975355e-7,0.0006384965,0.00018450945,0.17190932,0.000073049254,0.0062815207,0.16054904],"study_design_scores_gemma":[0.0005421124,0.00030516894,0.9791017,0.000016253493,0.0000267158,0.0000023570979,0.00019799975,0.00078879186,0.004829701,0.00017773925,0.013806599,0.00020483376],"about_ca_topic_score_codex":0.005119962,"about_ca_topic_score_gemma":0.0018076574,"teacher_disagreement_score":0.31916955,"about_ca_system_score_codex":0.00018998903,"about_ca_system_score_gemma":0.000056068686,"threshold_uncertainty_score":0.9997294},"labels":[],"label_agreement":null},{"id":"W2975748077","doi":"10.1007/s41669-019-00180-z","title":"Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Azacitidine; Medicine; Myeloid leukemia; Cost effectiveness; Internal medicine; Oncology; Cytarabine; Population; Hypomethylating agent; Environmental health; DNA methylation","score_opus":0.02051727135984825,"score_gpt":0.3295631370827624,"score_spread":0.30904586572291415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975748077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971776,0.000018240245,0.0000068140926,0.00022535006,0.00012500383,0.0023032597,0.000118891585,0.000011483922,0.025414972],"genre_scores_gemma":[0.99759,0.000067179746,0.00047880202,0.00028516797,0.00005832765,0.00009900809,0.0002529582,0.000053630414,0.0011149159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986708,0.000059191778,0.00035276177,0.00039326333,0.00023801079,0.00028596626],"domain_scores_gemma":[0.999078,0.000052980045,0.00019832837,0.00036708772,0.00018220914,0.000121445475],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006567334,0.00018898697,0.00045257583,0.00018589936,0.000023859042,0.000046715748,0.0003695638,0.00006410479,0.0037359716],"category_scores_gemma":[0.0000071756344,0.00015862522,0.000030722407,0.00009890501,0.000064568085,0.00044115834,0.00014580559,0.00025418794,0.0010115852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023697393,0.00075585116,0.8302199,0.00043249928,0.003561429,0.00006419597,0.0008753948,0.025689118,0.007804716,0.0012578989,0.027239561,0.078402035],"study_design_scores_gemma":[0.198482,0.006128869,0.57910633,0.0007502914,0.0020880722,0.000116638024,0.00035790552,0.12123547,0.05453187,0.0005135732,0.034601886,0.0020870944],"about_ca_topic_score_codex":0.0006240565,"about_ca_topic_score_gemma":0.00014332391,"teacher_disagreement_score":0.25111356,"about_ca_system_score_codex":0.0021640551,"about_ca_system_score_gemma":0.0019375357,"threshold_uncertainty_score":0.99976623},"labels":[],"label_agreement":null},{"id":"W3010862135","doi":"10.1007/s41669-020-00204-z","title":"Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada)","funders":"Janssen Pharmaceuticals","keywords":"Medicine; Rituximab; Follicular lymphoma; Cost effectiveness; Obinutuzumab; Systematic review; MEDLINE; Quality-adjusted life year; Bendamustine; Oncology; Internal medicine; Lymphoma","score_opus":0.32936076707084955,"score_gpt":0.47322178850499214,"score_spread":0.1438610214341426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010862135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02025334,0.9544085,0.0000035384408,0.00011069435,0.000043024247,0.024866527,0.0002620716,0.000011693208,0.000040604915],"genre_scores_gemma":[0.0046836385,0.991759,0.00017337978,0.00045515646,0.000018516128,0.0022826144,0.00052978046,0.00007175573,0.000026128335],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99412954,0.0020727348,0.0025199752,0.0008107923,0.00016619594,0.00030073838],"domain_scores_gemma":[0.9955641,0.0010989778,0.0022712818,0.0004788194,0.000070459515,0.00051636045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002344471,0.00063065864,0.008493211,0.00020411272,0.00006977221,0.00013045578,0.0002604912,0.00015134804,0.00002792349],"category_scores_gemma":[0.0002644143,0.00039761406,0.0002477108,0.0003365432,0.00007442606,0.00024208489,0.0003264604,0.00016809584,0.000013817103],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024347617,0.0016251142,0.06308495,0.5594091,0.00478862,0.000098980054,0.00014292983,0.000002961022,1.0707995e-7,0.000060736154,0.00057868543,0.3677731],"study_design_scores_gemma":[0.059379064,0.0014562085,0.10085652,0.30655313,0.010303024,0.00013425441,0.00005692618,0.00009744721,0.0000030607607,0.0000023661096,0.51992965,0.0012283494],"about_ca_topic_score_codex":0.0030432667,"about_ca_topic_score_gemma":0.0001639187,"teacher_disagreement_score":0.51935095,"about_ca_system_score_codex":0.0014894323,"about_ca_system_score_gemma":0.0008624193,"threshold_uncertainty_score":0.9998476},"labels":[],"label_agreement":null},{"id":"W3015688173","doi":"10.1007/s41669-020-00212-z","title":"Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative Study","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Tianjin University; National Natural Science Foundation of China","keywords":"Anxiety; CLARITY; Relevance (law); Qualitative research; Psychology; China; Mental health; Population; Clinical psychology; Gerontology; Medicine; Psychiatry; Environmental health; Geography; Sociology; Social science; Political science","score_opus":0.6214977604419405,"score_gpt":0.5467421121684448,"score_spread":0.07475564827349568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015688173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9221451,0.002153587,0.0004988236,0.06488504,0.0007531383,0.0035497984,0.00068070047,0.00006126086,0.0052725156],"genre_scores_gemma":[0.97556263,0.0004894224,0.00070267124,0.022101248,0.00040679553,0.0002885592,0.000057779882,0.00008597401,0.0003049013],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9908954,0.0014807045,0.005336966,0.001447498,0.0001403598,0.0006990746],"domain_scores_gemma":[0.9940401,0.0020795446,0.0025077441,0.0007324869,0.000052935495,0.00058722444],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.016184926,0.000476568,0.0019226207,0.00033973242,0.00024746612,0.00084558,0.0021052817,0.00014644791,0.004006015],"category_scores_gemma":[0.0031351293,0.00064265745,0.00017198136,0.00033956082,0.00011305287,0.0031893246,0.00092442037,0.00059318054,0.0067891157],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013423853,0.00082933804,0.16015472,0.0002688956,0.0008947532,0.000034114713,0.7500094,0.0012827901,0.000045374076,0.022724066,0.06192995,0.0004842056],"study_design_scores_gemma":[0.018036956,0.0011721216,0.099720314,0.0006647272,0.000102528065,0.000007864738,0.6859762,0.023789847,0.0001303446,0.15903535,0.008418737,0.002944978],"about_ca_topic_score_codex":0.05400373,"about_ca_topic_score_gemma":0.0023849276,"teacher_disagreement_score":0.1363113,"about_ca_system_score_codex":0.0016562684,"about_ca_system_score_gemma":0.0004289241,"threshold_uncertainty_score":0.9996025},"labels":[],"label_agreement":null},{"id":"W3016073506","doi":"10.1007/s41669-020-00215-w","title":"Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Anticholinergic; Medicine; Cohort; Overactive bladder; Emergency medicine; Cohort study; Health care; Anticholinergic agents; Physical therapy; Internal medicine; Alternative medicine","score_opus":0.030604975134650107,"score_gpt":0.35366453399302655,"score_spread":0.32305955885837645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016073506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9421545,0.00028255384,0.00001757963,0.050994787,0.000023895325,0.0018303819,0.00008072645,0.00002565292,0.004589901],"genre_scores_gemma":[0.9938639,0.0006505426,0.000103670034,0.0046428596,0.00009635443,0.00006096548,0.0001517387,0.000046651967,0.00038335603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986098,0.00014627186,0.0002833757,0.0004630575,0.0001388326,0.00035868317],"domain_scores_gemma":[0.9989567,0.00024920542,0.00018866555,0.00013326257,0.00013918651,0.0003329805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034408347,0.00022930298,0.0004993572,0.00008512077,0.00009356181,0.00012807452,0.00016409294,0.000087304725,0.00017795812],"category_scores_gemma":[0.00003238896,0.00016841943,0.000028243498,0.0002397276,0.000035192854,0.00057299074,0.00015666337,0.0006739218,0.000031578762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016504845,0.00040162474,0.917654,0.000252862,0.0021883762,0.00022905119,0.046251465,0.0045893355,0.0017165219,0.00014041584,0.003719729,0.006351776],"study_design_scores_gemma":[0.08104433,0.008733042,0.6431623,0.00061827956,0.0006536341,0.00039017014,0.01587789,0.17790483,0.015190362,0.00054000923,0.053615402,0.0022697158],"about_ca_topic_score_codex":0.0045350716,"about_ca_topic_score_gemma":0.00075642974,"teacher_disagreement_score":0.27449167,"about_ca_system_score_codex":0.00044274313,"about_ca_system_score_gemma":0.0003898535,"threshold_uncertainty_score":0.6867945},"labels":[],"label_agreement":null},{"id":"W3089359485","doi":"10.1007/s41669-020-00231-w","title":"Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada)","funders":"Janssen Pharmaceuticals","keywords":"EconLit; MEDLINE; Medicine; Systematic review; Economic evaluation; Quality of life (healthcare); Cochrane Library; Mantle cell lymphoma; Resource (disambiguation); Family medicine; Meta-analysis; Lymphoma; Political science; Pathology; Computer science","score_opus":0.044622184933162896,"score_gpt":0.3441055139569483,"score_spread":0.2994833290237854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089359485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723595,0.02275715,8.775415e-7,0.000754185,0.000022835538,0.0030171513,0.00023564593,0.0000049682935,0.0008477334],"genre_scores_gemma":[0.9831032,0.012242348,0.00022450175,0.0040628277,0.000016194734,0.00013542338,0.00016952548,0.000019433164,0.000026551304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850595,0.00017550321,0.0008571456,0.00026767174,0.00008515469,0.00010856293],"domain_scores_gemma":[0.99875474,0.00021214908,0.0005504603,0.00023996465,0.00007515418,0.0001675521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004591677,0.00015602385,0.0009539064,0.000049571056,0.000018273806,0.000045494562,0.00015967077,0.000034074434,0.0000829104],"category_scores_gemma":[0.00008857814,0.00012276902,0.00006268621,0.00007303713,0.000028322596,0.00025517595,0.0001242874,0.00004042037,0.000016038724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009981777,0.0010410923,0.8576708,0.13556841,0.0004409693,0.000003837512,0.00047068213,0.000034466488,0.000033378787,0.0002565259,0.002799228,0.0006824273],"study_design_scores_gemma":[0.064303376,0.0009514012,0.82438827,0.10137528,0.0014969286,0.0000057455927,0.00020524167,0.0015990235,0.0035592187,0.000011423068,0.0015189932,0.00058507995],"about_ca_topic_score_codex":0.00017235425,"about_ca_topic_score_gemma":0.000014817981,"teacher_disagreement_score":0.0633052,"about_ca_system_score_codex":0.0002303205,"about_ca_system_score_gemma":0.00019526729,"threshold_uncertainty_score":0.50063753},"labels":[],"label_agreement":null},{"id":"W3097148862","doi":"10.1007/s41669-020-00235-6","title":"Investigation of Factors Considered by Health Technology Assessment Agencies in Eight Countries","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacoeconomics; Health technology; Excellence; Economic evaluation; Nice; Medicine; Health economics; Health care; Stakeholder; Transparency (behavior); Family medicine; Economic growth; Political science; Public relations; Economics; Intensive care medicine","score_opus":0.5166002091916603,"score_gpt":0.5059722978757282,"score_spread":0.010627911315932104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097148862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7497206,0.0021677339,0.00059456914,0.24171707,0.0003551876,0.001829774,0.0017197082,0.000047948382,0.0018474562],"genre_scores_gemma":[0.95072955,0.00075772835,0.0030434637,0.04490676,0.000069685324,0.0001478756,0.00021392963,0.00004370594,0.000087294015],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99394655,0.0002852352,0.004573954,0.0006904619,0.00006105375,0.0004427461],"domain_scores_gemma":[0.9954744,0.00053807895,0.0032932146,0.00034322514,0.000052088537,0.00029900827],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0063694795,0.00025823803,0.0015295065,0.00036949854,0.00014796612,0.00013797305,0.0008124187,0.00014085491,0.00096170994],"category_scores_gemma":[0.0005513366,0.0003484336,0.00007535584,0.00028960142,0.00019365958,0.0009812863,0.00027310097,0.00027985446,0.00032489444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042885407,0.00006552253,0.65155566,0.00063637405,0.00019819378,0.0000011431671,0.009241369,0.00048667722,0.0002644444,0.1381637,0.19924784,0.00009619105],"study_design_scores_gemma":[0.016656507,0.0010610094,0.07675262,0.00040868585,0.000052151107,0.000009772261,0.038195692,0.06149787,0.011958999,0.08859296,0.70135444,0.0034592727],"about_ca_topic_score_codex":0.002322225,"about_ca_topic_score_gemma":0.000224168,"teacher_disagreement_score":0.57480305,"about_ca_system_score_codex":0.0011373506,"about_ca_system_score_gemma":0.0009786767,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W3103580978","doi":"10.1007/s41669-020-00241-8","title":"The Actual Operative Costs of Liver Transplantation and Normothermic Machine Perfusion in a Canadian Setting","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Organ Transplantation Techniques and Outcomes","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Liver transplantation; Procurement; Medicine; Transplantation; Machine perfusion; Total cost; Perfusion; Marginal cost; Operations management; Surgery; Emergency medicine; Business; Internal medicine; Economics; Accounting","score_opus":0.01892164509931704,"score_gpt":0.3280509178730727,"score_spread":0.3091292727737557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103580978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875887,0.00023060355,0.000058426456,0.009083748,0.000023690298,0.00078687357,0.00013663933,0.00001030675,0.0020810363],"genre_scores_gemma":[0.9879128,0.0075563267,0.00040382377,0.0039990116,0.000021419211,0.0000119067845,0.000045187368,0.000013434405,0.000036135323],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994558,0.00003512844,0.00020976574,0.00013666286,0.000032505508,0.00013012461],"domain_scores_gemma":[0.99964964,0.0000793002,0.000050928196,0.000051013838,0.000017215198,0.00015192607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020242909,0.000082350285,0.00015599391,0.00004300735,0.00008045949,0.000039166483,0.00012354225,0.000028228122,0.00018150476],"category_scores_gemma":[0.000009225694,0.00006412698,0.000020135234,0.000045451747,0.00003082926,0.00014348705,0.000019793863,0.00011893022,0.0000069169782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066146525,0.00017135672,0.46892354,0.0014697763,0.00034750672,0.0005835251,0.08846069,0.00021849113,0.10081163,0.004463827,0.0019495783,0.3259854],"study_design_scores_gemma":[0.0207164,0.00090101047,0.38948634,0.00044832384,0.0006511681,0.00036029407,0.0021079902,0.15939918,0.40665144,0.00009474064,0.018252509,0.00093057373],"about_ca_topic_score_codex":0.07504242,"about_ca_topic_score_gemma":0.1080588,"teacher_disagreement_score":0.32505485,"about_ca_system_score_codex":0.000086010325,"about_ca_system_score_gemma":0.00016324704,"threshold_uncertainty_score":0.93111694},"labels":[],"label_agreement":null},{"id":"W3121637752","doi":"10.1007/s41669-021-00257-8","title":"The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Promotion and Cardiovascular Prevention","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Alberta Innovates; Sanofi","keywords":"Medicine; Secondary prevention; Dyslipidemia; Health care; Disease; Disease burden; Cardiovascular event; Internal medicine; Emergency medicine; Pediatrics","score_opus":0.03160288090312003,"score_gpt":0.35144137744802484,"score_spread":0.3198384965449048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121637752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8745986,0.028159423,0.011706744,0.060644,0.0015468148,0.021106042,0.0006296061,0.00010710209,0.0015016634],"genre_scores_gemma":[0.9833321,0.010814005,0.0008578296,0.0016536154,0.00048328817,0.0017407702,0.00035358933,0.000055220717,0.00070955564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806476,0.0006292704,0.00036241653,0.00045556633,0.00014547228,0.00034250866],"domain_scores_gemma":[0.9986259,0.0000869002,0.000097011136,0.00064385467,0.00017898071,0.00036736627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029656787,0.00014495132,0.0004286986,0.000037222155,0.0002668743,0.00009693596,0.00021598577,0.00004771763,0.00007624603],"category_scores_gemma":[0.00008978523,0.00011436817,0.00044058645,0.00011167758,0.000033373024,0.00015874635,0.00012314033,0.00025135628,0.000040487903],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026932815,0.0002821325,0.010772165,0.0014094479,0.004200212,0.0002582337,0.0006586552,0.0050356956,0.0000121704425,0.0017093492,0.0025308568,0.9704378],"study_design_scores_gemma":[0.0408091,0.00026034986,0.059753325,0.00076068233,0.0017560065,0.00010916338,0.001082031,0.008827553,0.0005709862,0.0014433832,0.88407487,0.0005525512],"about_ca_topic_score_codex":0.0015002319,"about_ca_topic_score_gemma":0.00038817295,"teacher_disagreement_score":0.96988523,"about_ca_system_score_codex":0.0002525856,"about_ca_system_score_gemma":0.00075174344,"threshold_uncertainty_score":0.46637988},"labels":[],"label_agreement":null},{"id":"W3125780982","doi":"10.1007/s41669-020-00244-5","title":"An Exploration on Attribute Non-attendance Using Discrete Choice Experiment Data from the Irish EQ-5D-5L National Valuation Study","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; Simon Fraser University; Vancouver Coastal Health","funders":"Health Research Board","keywords":"Valuation (finance); EQ-5D; Attendance; Irish; Latent class model; Discrete choice; Actuarial science; Quality-adjusted life year; Health care; Psychology; Econometrics; Medicine; Computer science; Health related quality of life; Economics; Machine learning; Cost effectiveness; Risk analysis (engineering); Disease","score_opus":0.8063207396074529,"score_gpt":0.5751746631831023,"score_spread":0.2311460764243506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125780982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93436533,0.00093713857,0.015340838,0.03366689,0.002572282,0.004095157,0.007038669,0.000062558036,0.0019211444],"genre_scores_gemma":[0.9666037,0.00016262187,0.0029665967,0.023782289,0.0019681437,0.00047521677,0.0037833827,0.0000897786,0.00016828108],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99320036,0.0010199614,0.003406157,0.0016786089,0.00023269614,0.00046221266],"domain_scores_gemma":[0.99390185,0.0014724337,0.0022697027,0.0018978206,0.00021699152,0.00024121156],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.016467256,0.00037098918,0.00095098047,0.00013742331,0.0007715189,0.0012279083,0.0023344941,0.000106591826,0.0012978734],"category_scores_gemma":[0.0012372384,0.00043590428,0.000093911745,0.00021995275,0.00005997385,0.00624946,0.0008497511,0.00032858696,0.0016672238],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006140036,0.0067073153,0.29747495,0.00019334636,0.0032224962,0.00001797427,0.037161253,0.2123659,0.001909196,0.01769462,0.4207627,0.0018762606],"study_design_scores_gemma":[0.0076798373,0.00026782276,0.052492388,0.00012164173,0.000120270655,0.0000048514135,0.015106698,0.8192431,0.00078333,0.0077008377,0.09494832,0.0015309105],"about_ca_topic_score_codex":0.0058904365,"about_ca_topic_score_gemma":0.0011431684,"teacher_disagreement_score":0.6068772,"about_ca_system_score_codex":0.001389812,"about_ca_system_score_gemma":0.0007053504,"threshold_uncertainty_score":0.99980927},"labels":[],"label_agreement":null},{"id":"W3154274729","doi":"10.1007/s41669-021-00263-w","title":"Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact","funders":"","keywords":"Medicine; MEDLINE; Economic evaluation; Oncology; Family medicine; Internal medicine; Medical physics; Pathology","score_opus":0.670614332465464,"score_gpt":0.6442023617784887,"score_spread":0.026411970686975317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154274729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89741516,0.02258815,0.004529456,0.018576078,0.0038382846,0.00896978,0.0019241186,0.000055498855,0.042103466],"genre_scores_gemma":[0.94581944,0.0020904064,0.03965331,0.009668724,0.00021988826,0.0014202872,0.00034190732,0.00013274331,0.0006533149],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98632824,0.005040264,0.007044858,0.00103835,0.00007251927,0.00047576157],"domain_scores_gemma":[0.9908583,0.0042790566,0.0036972563,0.0007401526,0.0001893422,0.00023588324],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.09903752,0.00029955574,0.002852704,0.00046102906,0.00010495736,0.0002104654,0.00074017834,0.00021413766,0.0016314226],"category_scores_gemma":[0.005877104,0.00041482382,0.00012213938,0.00021543552,0.000098848475,0.0010211598,0.0005014692,0.00025944013,0.000547856],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008727038,0.0026977595,0.5184164,0.045128167,0.0042550103,0.00003285194,0.023506878,0.023421468,0.0007292224,0.3148028,0.047265906,0.018870855],"study_design_scores_gemma":[0.02070106,0.00040278907,0.19062442,0.002238296,0.00032481868,0.00014782717,0.0052965316,0.6693891,0.0019330779,0.07989773,0.026212895,0.0028314241],"about_ca_topic_score_codex":0.009779416,"about_ca_topic_score_gemma":0.0053351247,"teacher_disagreement_score":0.64596766,"about_ca_system_score_codex":0.0023357368,"about_ca_system_score_gemma":0.0016981331,"threshold_uncertainty_score":0.99983037},"labels":[],"label_agreement":null},{"id":"W3157834287","doi":"10.1007/s41669-021-00267-6","title":"Cost-effectiveness of a Province-wide Quality Improvement Initiative for Reducing Potentially Inappropriate Use of Antipsychotics in Long-Term Care in British Columbia, Canada","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Geriatric Care and Nursing Homes","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; BC Innovation Council; University of British Columbia; Brock University","funders":"Michael Smith Health Research BC","keywords":"Medicine; Quality-adjusted life year; Incremental cost-effectiveness ratio; Cost–utility analysis; Cohort; Baseline (sea); Cost effectiveness; Quality of life (healthcare); Cost–benefit analysis; Demography; Emergency medicine; Actuarial science; Pediatrics; Internal medicine","score_opus":0.10944140727985129,"score_gpt":0.4339944316592042,"score_spread":0.3245530243793529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157834287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910457,0.0001982939,0.000163698,0.000121163706,0.0011952735,0.005916476,0.0012449475,0.000005732144,0.00010870004],"genre_scores_gemma":[0.9978626,0.00021128364,0.0005949221,0.0002763512,0.000042342497,0.0005180076,0.00035001652,0.000033052373,0.00011145203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970843,0.0007624192,0.0011698639,0.0004611653,0.000104600054,0.0004176312],"domain_scores_gemma":[0.9974128,0.0010763764,0.000663822,0.00027621424,0.00047937204,0.00009140962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012278581,0.00013287207,0.0007569,0.00006530326,0.0001337346,0.000081895836,0.0003197418,0.000105433246,0.00006941554],"category_scores_gemma":[0.0002481026,0.00022082985,0.00007689196,0.00018429836,0.000039947772,0.00033406622,0.0003018172,0.00030776436,4.414987e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020428656,0.00062331156,0.9311663,0.006648214,0.00018510074,0.00006350039,0.0044707363,0.00050315843,0.0038915838,0.000019579133,0.0015931656,0.048792507],"study_design_scores_gemma":[0.009860969,0.00014476491,0.9732856,0.0015500431,0.000065872606,0.0000014089304,0.0064730505,0.000086945474,0.007554097,0.00011282964,0.0005477623,0.00031661446],"about_ca_topic_score_codex":0.91321313,"about_ca_topic_score_gemma":0.9921372,"teacher_disagreement_score":0.078924015,"about_ca_system_score_codex":0.0013816124,"about_ca_system_score_gemma":0.006340187,"threshold_uncertainty_score":0.99929297},"labels":[],"label_agreement":null},{"id":"W3168701893","doi":"10.1007/s41669-021-00275-6","title":"Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto; University Health Network","funders":"Addis Ababa University","keywords":"Dolutegravir; Efavirenz; Human immunodeficiency virus (HIV); Medicine; Virology; Tenofovir; Second line; Pediatrics; Antiretroviral therapy; First line; Internal medicine; Viral load","score_opus":0.05826420296885351,"score_gpt":0.3741730334568439,"score_spread":0.31590883048799034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168701893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069786,0.00008077891,0.000013621799,0.0029689453,0.00017722101,0.0016365445,0.00030098922,0.00001752813,0.0041065295],"genre_scores_gemma":[0.99145615,0.00048194765,0.0018048694,0.0005633025,0.000021685344,0.00038733607,0.0022730073,0.000031811433,0.0029798604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976381,0.00016324944,0.000903931,0.00071714475,0.00017121324,0.0004063641],"domain_scores_gemma":[0.99849296,0.0003171538,0.00024756836,0.00054824457,0.00016557622,0.00022851664],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003485109,0.00035841443,0.0011690585,0.0005526785,0.000057082096,0.000043155316,0.00026385064,0.00012241075,0.0012023271],"category_scores_gemma":[0.000104667226,0.0003414692,0.0002815435,0.00090083486,0.00005999339,0.00017537996,0.00017283358,0.0002068237,0.00010582778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005740146,0.0050875973,0.97160625,0.000058348134,0.0030409489,0.00020804127,0.0016835402,0.0013303248,0.000055499702,0.00018554492,0.0006046874,0.010399065],"study_design_scores_gemma":[0.24222754,0.0018580985,0.55764884,0.00048372295,0.01079532,0.000005603702,0.0015511534,0.07815851,0.06347983,0.00019889827,0.04188877,0.0017037335],"about_ca_topic_score_codex":0.002455124,"about_ca_topic_score_gemma":0.011495701,"teacher_disagreement_score":0.41395745,"about_ca_system_score_codex":0.0012811711,"about_ca_system_score_gemma":0.000807315,"threshold_uncertainty_score":0.99990374},"labels":[],"label_agreement":null},{"id":"W3177377347","doi":"10.1007/s41669-021-00279-2","title":"Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Health technology; Agency (philosophy); Multivariate analysis; Actuarial science; Medicine; Business; Health care; Economics; Economic growth; Sociology; Internal medicine","score_opus":0.38378485757298003,"score_gpt":0.5879422646440101,"score_spread":0.20415740707103008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177377347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033864914,0.97568756,0.00067598134,0.00016467203,0.0014347561,0.009374181,0.008147496,0.000011432764,0.0011174498],"genre_scores_gemma":[0.0001435443,0.9895031,0.00464718,0.0024445334,0.0002030925,0.0021893233,0.00031524262,0.00019384678,0.00036016823],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98592263,0.00017993465,0.011529607,0.0016101423,0.000092866874,0.0006648017],"domain_scores_gemma":[0.981361,0.0023945495,0.01464872,0.0010933904,0.00024779746,0.00025458753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012400187,0.0008183458,0.0083748065,0.0005270912,0.00021892817,0.00040915675,0.0022051402,0.0004812877,0.00073566264],"category_scores_gemma":[0.0008211703,0.00096214225,0.00080553826,0.0003811069,0.00010781182,0.0012424317,0.0011758991,0.00036065772,0.000053968502],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096036485,0.00087164954,0.011074916,0.81276923,0.0031417615,0.000005796539,0.00067723676,0.00041452842,0.0000017400481,0.0015393021,0.015982708,0.15342508],"study_design_scores_gemma":[0.006534964,0.0001162655,0.0005110645,0.24537234,0.0023043992,0.00003370815,0.0000530758,0.020992436,0.000025700527,0.00049588864,0.72157025,0.0019898869],"about_ca_topic_score_codex":0.0014383185,"about_ca_topic_score_gemma":0.00007678043,"teacher_disagreement_score":0.70558757,"about_ca_system_score_codex":0.0014210639,"about_ca_system_score_gemma":0.0018415649,"threshold_uncertainty_score":0.9992829},"labels":[],"label_agreement":null},{"id":"W3185045240","doi":"10.1007/s41669-021-00286-3","title":"Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Imatinib; Internal medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Tyrosine kinase; Cost effectiveness; Oncology; Cancer","score_opus":0.10076930907736435,"score_gpt":0.41178376477177653,"score_spread":0.31101445569441216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185045240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814152,0.001732076,0.00014221168,0.0019820784,0.00065426604,0.010771688,0.0015844058,0.000017034465,0.0017010272],"genre_scores_gemma":[0.9935394,0.0015407862,0.00036867894,0.0003497599,0.0002716962,0.0029925103,0.00043477415,0.00009978498,0.00040263956],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99724174,0.00024119826,0.0010065761,0.00081567233,0.00014469157,0.0005501422],"domain_scores_gemma":[0.9959984,0.0022808185,0.00036672223,0.0009783122,0.00018214252,0.00019364181],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010590932,0.0004915077,0.0012230914,0.00012506178,0.00014435132,0.000060828595,0.0007236337,0.00011553948,0.0007566608],"category_scores_gemma":[0.000067672234,0.000359601,0.0003746422,0.00018147001,0.00017236244,0.00026132428,0.0003341264,0.00021045194,0.00006308185],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04082122,0.0025813072,0.0014477588,0.00095569436,0.009364856,0.000059177102,0.0046579787,0.73930055,0.14951113,0.00203258,0.0018449377,0.047422834],"study_design_scores_gemma":[0.079187155,0.0033172008,0.004730876,0.0003011567,0.0016619648,0.000040975967,0.00036948983,0.25309905,0.6500848,0.00027763454,0.006405055,0.0005246444],"about_ca_topic_score_codex":0.00074424996,"about_ca_topic_score_gemma":0.001843146,"teacher_disagreement_score":0.5005737,"about_ca_system_score_codex":0.011738013,"about_ca_system_score_gemma":0.0052185073,"threshold_uncertainty_score":0.9998856},"labels":[],"label_agreement":null},{"id":"W3203942868","doi":"10.1007/s41669-021-00300-8","title":"Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Evolocumab; Medicine; Ezetimibe; Familial hypercholesterolemia; Dyslipidemia; Statin; Internal medicine; Quality-adjusted life year; Alirocumab; Cost effectiveness; Cholesterol; Disease; Lipoprotein","score_opus":0.11329147644652462,"score_gpt":0.427569372084309,"score_spread":0.3142778956377844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203942868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920399,0.0023478442,0.0006024463,0.0007835559,0.00011940453,0.0035162594,0.00016033564,0.0000021613964,0.00042806147],"genre_scores_gemma":[0.9976152,0.0011199365,0.00024218742,0.0002712325,0.00007338559,0.0005813323,0.000054601845,0.0000123552,0.000029724159],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987509,0.00026533552,0.0004937162,0.00022199562,0.00011660698,0.00015141434],"domain_scores_gemma":[0.9980753,0.00081319915,0.00025487124,0.00068051176,0.00013720753,0.000038877053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021550972,0.00011378728,0.000951387,0.000091641436,0.00004046492,0.000012070602,0.00027050043,0.000041513606,0.000089453366],"category_scores_gemma":[0.00006937576,0.0000682609,0.0005393949,0.00038140384,0.000057953723,0.00005501674,0.000054045024,0.00006713874,7.1902144e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008283414,0.005899205,0.22270125,0.0025219268,0.06654343,0.000037655245,0.008066596,0.044575926,0.020575857,0.0058388007,0.0011256174,0.6138303],"study_design_scores_gemma":[0.030223817,0.0013845336,0.52512014,0.000232654,0.023639979,0.00001856814,0.0020709392,0.035243202,0.28164625,0.00041273772,0.099634506,0.00037269387],"about_ca_topic_score_codex":0.0026215587,"about_ca_topic_score_gemma":0.00042951686,"teacher_disagreement_score":0.6134576,"about_ca_system_score_codex":0.00018345076,"about_ca_system_score_gemma":0.00031422125,"threshold_uncertainty_score":0.396303},"labels":[],"label_agreement":null},{"id":"W3205515305","doi":"10.1007/s41669-021-00304-4","title":"Budget Impact Analysis of an Epigenetic Test Used for Diagnosing Fetal Alcohol Spectrum Disorder from the Perspective of a Laboratory Budget Holder in Manitoba, Canada","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Prenatal Substance Exposure Effects","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation; University of Manitoba; Institute for Clinical Evaluative Sciences; University of Calgary","funders":"Kids Brain Health Network; Canada Research Chairs","keywords":"Fetal Alcohol Spectrum Disorder; Prenatal alcohol exposure; Population; Medicine; DNA methylation; Fetal alcohol syndrome; Environmental health; Demography; Biology; Genetics; Pregnancy","score_opus":0.020683420006045512,"score_gpt":0.3300818351518783,"score_spread":0.3093984151458328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205515305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920917,0.0014591971,0.000039151448,0.0013765955,0.00016706457,0.0013733367,0.0033923285,0.000006962913,0.00009364647],"genre_scores_gemma":[0.99830556,0.00009424887,0.00033280626,0.0006289944,0.00010927619,0.00010989131,0.0003658461,0.00004275654,0.000010595968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983722,0.00015890745,0.0005107068,0.000491755,0.00014602298,0.00032041842],"domain_scores_gemma":[0.9974217,0.0013987796,0.000301365,0.00055057305,0.00016996486,0.0001576512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004276539,0.00023763665,0.00085670594,0.00012741855,0.000056893285,0.00005403255,0.00046963047,0.000057534657,0.00028403784],"category_scores_gemma":[0.00032561205,0.00020708266,0.00018928955,0.0006059144,0.00007272004,0.00027142765,0.00016788396,0.00019582255,0.0000013461827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045890795,0.00070248125,0.93228644,0.000044488224,0.0033039013,0.00008932731,0.0016565324,0.003657054,0.056182586,0.000042438434,0.0008246274,0.0007512267],"study_design_scores_gemma":[0.005929472,0.00020253517,0.75287855,0.00006620699,0.0017952378,0.0000031762067,0.0029106964,0.016035598,0.21941333,0.00019383896,0.00025420298,0.00031717698],"about_ca_topic_score_codex":0.57017606,"about_ca_topic_score_gemma":0.9244194,"teacher_disagreement_score":0.3542433,"about_ca_system_score_codex":0.00070077035,"about_ca_system_score_gemma":0.0015273581,"threshold_uncertainty_score":0.8444586},"labels":[],"label_agreement":null},{"id":"W3210263997","doi":"10.1007/s41669-021-00309-z","title":"Community Distribution of Naloxone: A Systematic Review of Economic Evaluations","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"(+)-Naloxone; EconLit; Medicine; Quality (philosophy); Economic evaluation; MEDLINE; Actuarial science; Business; Opioid; Political science","score_opus":0.11850715075104147,"score_gpt":0.49336442256005686,"score_spread":0.3748572718090154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210263997","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025512707,0.9859895,0.000015451587,0.00013736398,0.00020546098,0.009912416,0.002334302,0.000012300726,0.0013676514],"genre_scores_gemma":[0.000031564283,0.98771054,0.00017563089,0.00017924035,0.000031753665,0.0014412048,0.01014293,0.000061609,0.00022554446],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99553025,0.0012410596,0.002577213,0.0003298007,0.00012456304,0.00019712093],"domain_scores_gemma":[0.9955794,0.0004579617,0.0022392473,0.001382747,0.00020525245,0.0001353747],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021140072,0.00043806838,0.0065002646,0.00010935008,0.000080081816,0.000034788285,0.00086569483,0.00013065425,0.0008178634],"category_scores_gemma":[0.00027313235,0.0003914111,0.0010116716,0.00015907426,0.00006656259,0.00014553992,0.0005810989,0.0004449059,0.00018005726],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067187652,0.00047227996,0.0000031092559,0.98086905,0.0023601218,0.0000019301012,0.000057083227,0.0000010984799,3.0518618e-7,0.0003447039,0.002124613,0.0137589825],"study_design_scores_gemma":[0.00095070055,0.00008717719,0.0000030160509,0.84452105,0.02918131,0.00006240246,0.00006980769,0.000039830902,0.000021838234,0.000024079278,0.12476723,0.00027155378],"about_ca_topic_score_codex":0.00037453414,"about_ca_topic_score_gemma":0.000012455553,"teacher_disagreement_score":0.136348,"about_ca_system_score_codex":0.0010973536,"about_ca_system_score_gemma":0.0026335733,"threshold_uncertainty_score":0.9998538},"labels":[],"label_agreement":null},{"id":"W3215778396","doi":"10.1007/s41669-021-00311-5","title":"Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Consumers, Health, Agriculture and Food Executive Agency; Directorate-General for Health and Consumers","keywords":"Health technology; Transparency (behavior); Scope (computer science); Negotiation; European union; Transformative learning; Business; Political science; Public economics; Process management; Medicine; Health care; Psychology; Computer science; Economics","score_opus":0.6845194897058882,"score_gpt":0.5941363569088085,"score_spread":0.09038313279707966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215778396","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00056597416,0.955744,0.002162784,0.025813859,0.00069769815,0.005837331,0.009024967,0.000032209577,0.00012114384],"genre_scores_gemma":[0.0006644922,0.9881464,0.003130478,0.003112858,0.00020524574,0.0041064844,0.000390896,0.00007572671,0.00016738543],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904242,0.00062087364,0.0067981197,0.001535537,0.000049551425,0.00057168247],"domain_scores_gemma":[0.98386574,0.010424795,0.0045795613,0.000779203,0.00008264173,0.00026806205],"candidate_categories":["metaepi_narrow","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.012170931,0.00054188154,0.0055877226,0.00073226896,0.0004469192,0.0012403671,0.0010762315,0.00039345177,0.00011105994],"category_scores_gemma":[0.0018745566,0.0006594304,0.00016199386,0.00021445254,0.00017334521,0.0010631448,0.00075106934,0.00045503603,0.000050701467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034551522,0.0003140003,0.051632185,0.048294745,0.001571082,0.0000039623583,0.0014654655,0.00007333434,1.3417163e-7,0.6815272,0.03788323,0.1772001],"study_design_scores_gemma":[0.00082891335,0.00006121579,0.001046761,0.012591429,0.000072692485,0.000015851896,0.0006177606,0.0012811112,4.7821306e-8,0.013977228,0.9688416,0.000665358],"about_ca_topic_score_codex":0.003535036,"about_ca_topic_score_gemma":0.0005599276,"teacher_disagreement_score":0.9309584,"about_ca_system_score_codex":0.0015520302,"about_ca_system_score_gemma":0.0017735972,"threshold_uncertainty_score":0.99979645},"labels":[],"label_agreement":null},{"id":"W4206796574","doi":"10.1007/s41669-021-00321-3","title":"Prevalence and Cost of Care for Parkinson’s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds National de la Recherche Luxembourg","keywords":"Health care; Disease; National health insurance; Work (physics); Health insurance; National Insurance; Health data; Health economics","score_opus":0.07838141638964154,"score_gpt":0.410851852721078,"score_spread":0.33247043633143647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206796574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.965855,0.002114929,0.000013516601,0.000354955,0.000057772675,0.001491254,0.030034626,0.0000045631955,0.00007338184],"genre_scores_gemma":[0.99553865,0.0005436678,0.0003694439,0.00043507098,0.000015591108,0.00028481564,0.00277155,0.000014167601,0.000027023549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989166,0.000070467715,0.00031535802,0.00043150675,0.0001332197,0.00013283589],"domain_scores_gemma":[0.9990896,0.000059278544,0.0002042231,0.00036050213,0.000087854496,0.00019857123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035280947,0.000103019906,0.00039946858,0.00020823114,0.000081486774,0.000014913487,0.00042324304,0.000013868415,0.00017893863],"category_scores_gemma":[0.000024264622,0.00011446217,0.00005713795,0.00016737457,0.000026534157,0.00026028798,0.0004227657,0.00006267447,3.426547e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018852638,0.00046592506,0.9906941,0.00048786934,0.0004779884,0.000007625903,0.0003654976,0.0018089309,0.00005493755,0.00033532237,0.00008980495,0.00332674],"study_design_scores_gemma":[0.003958039,0.00015837661,0.93356663,0.000029709307,0.0007845093,0.0000010499938,0.0002468235,0.050264195,0.00016410399,0.00015508967,0.010553236,0.00011823307],"about_ca_topic_score_codex":0.00067703053,"about_ca_topic_score_gemma":0.0002900956,"teacher_disagreement_score":0.05712746,"about_ca_system_score_codex":0.00020573457,"about_ca_system_score_gemma":0.00042859613,"threshold_uncertainty_score":0.4667632},"labels":[],"label_agreement":null},{"id":"W4224952615","doi":"10.1007/s41669-022-00330-w","title":"Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Disease; Perspective (graphical); Medicine; Intensive care medicine; Medical costs; Health care; Pathology; Computer science; Political science","score_opus":0.018449751082903452,"score_gpt":0.36386667155065927,"score_spread":0.3454169204677558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224952615","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013551798,0.99204797,0.000001822125,0.00056205277,0.000058684665,0.00415427,0.0006149309,0.000010852291,0.0011942335],"genre_scores_gemma":[0.00046477112,0.99705064,0.000019579298,0.0012371278,0.00003520238,0.0004516765,0.0004484998,0.000047700214,0.0002448271],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9973855,0.00032067084,0.0010417975,0.0007186273,0.00029956514,0.00023386478],"domain_scores_gemma":[0.99750525,0.0004500335,0.0005595973,0.00039906258,0.000032209467,0.001053841],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007819185,0.00044385585,0.0045522014,0.00021701593,0.00009909386,0.000056427405,0.00037083455,0.00020422967,0.004159336],"category_scores_gemma":[0.00024468018,0.0003236007,0.00038108713,0.00027327196,0.00014283377,0.00008599682,0.00074691494,0.0005176182,0.000012806139],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013060668,0.0007351212,0.0008816226,0.9369849,0.01964022,0.0006373186,0.0002699214,3.8663015e-7,9.8375374e-8,0.000024154437,0.0016840188,0.039011627],"study_design_scores_gemma":[0.011444217,0.00037220732,0.00014548737,0.3164686,0.50028574,0.00040671523,0.0008381801,0.0038861725,3.3361854e-7,0.000038181308,0.16477801,0.0013361352],"about_ca_topic_score_codex":0.0009064053,"about_ca_topic_score_gemma":0.000024608145,"teacher_disagreement_score":0.6205163,"about_ca_system_score_codex":0.00020680082,"about_ca_system_score_gemma":0.00080956623,"threshold_uncertainty_score":0.9999216},"labels":[],"label_agreement":null},{"id":"W4225004644","doi":"10.1007/s41669-022-00331-9","title":"Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Population Health Research Institute; Takeda (Canada)","funders":"","keywords":"Vedolizumab; Medicine; Tofacitinib; Golimumab; Ustekinumab; Ulcerative colitis; Infliximab; Adalimumab; Internal medicine; Disease","score_opus":0.023059148200213,"score_gpt":0.31087088664332546,"score_spread":0.2878117384431125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225004644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948163,0.00005451799,0.000030369087,0.00003057788,0.00017757085,0.0020087834,0.0023136793,9.721439e-7,0.00056725316],"genre_scores_gemma":[0.9983182,0.000053569147,0.00004970385,0.00009698474,0.000019560755,0.0011049715,0.00023852395,0.000018664117,0.000099836514],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913746,0.00016547897,0.00024886616,0.0002359843,0.000036967267,0.00017523122],"domain_scores_gemma":[0.9995125,0.00006053606,0.00014991836,0.00017561039,0.000046801608,0.000054637927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019155213,0.00011112615,0.00023715588,0.000023456765,0.000048866088,0.000006701345,0.0002935041,0.000015825191,0.000080583515],"category_scores_gemma":[0.000011690071,0.00012854664,0.000057979287,0.000025517389,0.000028553744,0.000004814948,0.00016347872,0.000027676171,3.977001e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2533408,0.0030683402,0.10537995,0.0015222984,0.0026873192,0.0015775168,0.001590183,0.29574266,0.28535044,0.00547363,0.013389208,0.03087764],"study_design_scores_gemma":[0.031355843,0.0023002366,0.1171165,0.00004552856,0.00014513005,0.000102793776,0.0011269237,0.007563861,0.75973433,0.00047502268,0.079103135,0.00093071687],"about_ca_topic_score_codex":0.1733308,"about_ca_topic_score_gemma":0.3700286,"teacher_disagreement_score":0.47438386,"about_ca_system_score_codex":0.00084121624,"about_ca_system_score_gemma":0.0016891861,"threshold_uncertainty_score":0.83217406},"labels":[],"label_agreement":null},{"id":"W4285391949","doi":"10.1007/s41669-022-00347-1","title":"Using Health Economics to Inform Immunization Policy Across All Levels of Government","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Government (linguistics); Scope (computer science); Immunization; Work (physics); Process (computing); Health care; Business; Public relations; Political science; Economic growth; Medicine; Economics; Computer science","score_opus":0.15821961852435548,"score_gpt":0.47921207765072615,"score_spread":0.32099245912637064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285391949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968836,0.000077067576,0.00017989376,0.015330296,0.00044237854,0.0010622666,0.0008806752,0.00001534875,0.013176048],"genre_scores_gemma":[0.98578566,0.0002902225,0.00078022655,0.011708634,0.00019267156,0.00003663037,0.0000136768695,0.000021613763,0.0011706755],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873585,0.000102828606,0.00046527584,0.00019902273,0.00011656708,0.00038043555],"domain_scores_gemma":[0.9991869,0.000044213084,0.00036242546,0.00020348314,0.00002653305,0.00017648879],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014366625,0.00010307777,0.00025943638,0.00004790046,0.0010289657,0.00017270645,0.00096968,0.00002115454,0.001105228],"category_scores_gemma":[0.000030449693,0.00013833144,0.00005676744,0.00019173806,0.000011055837,0.0006883565,0.001186706,0.000104995626,0.000021403599],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070310617,0.0006784699,0.02899094,0.000107253,0.00055576843,0.000004094789,0.2821025,0.2232534,0.0024381808,0.23005013,0.02703281,0.20408335],"study_design_scores_gemma":[0.0013269522,0.000108031134,0.003746949,0.0000069857365,0.000012919215,0.0000020962239,0.010221681,0.0023086586,0.0011158368,0.0013908755,0.9794272,0.00033179545],"about_ca_topic_score_codex":0.015303816,"about_ca_topic_score_gemma":0.002205599,"teacher_disagreement_score":0.9523944,"about_ca_system_score_codex":0.0026055672,"about_ca_system_score_gemma":0.001009057,"threshold_uncertainty_score":0.9998079},"labels":[],"label_agreement":null},{"id":"W4286494041","doi":"10.1007/s41669-022-00355-1","title":"Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX)","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pregnancy and preeclampsia studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Oxford University Hospitals NHS Foundation Trust; Dalhousie University; University of Oxford; Health Technology Assessment Programme; Imperial College London; University of Bristol; National Institute for Health and Care Research; University Hospital Southampton NHS Foundation Trust","keywords":"Medicine; Obstetrics; Confidence interval; Gestation; Pregnancy; Pediatrics","score_opus":0.077040696318964,"score_gpt":0.366985040062162,"score_spread":0.289944343743198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286494041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834518,0.00064595387,0.00026460816,0.00042966093,0.00029859386,0.0047803563,0.0013432765,0.00004572029,0.008740057],"genre_scores_gemma":[0.99280983,0.0005009396,0.0012049628,0.0009242285,0.000034451507,0.002151055,0.0002520826,0.000030403204,0.0020920238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998219,0.00010426367,0.0006284914,0.0005474782,0.00014254505,0.00035818486],"domain_scores_gemma":[0.99878997,0.00020290368,0.0003129517,0.0005229984,0.00004893064,0.00012223511],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063977326,0.0002327804,0.00084543927,0.0002490606,0.0003068523,0.000046426638,0.0006610904,0.000035956735,0.0015825563],"category_scores_gemma":[0.000013369917,0.00022152328,0.00032900003,0.00029987516,0.000061211394,0.00022079001,0.0011362792,0.00018184095,0.000005374374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20695096,0.0039113276,0.47297558,0.002787455,0.11524663,0.0003958384,0.042167146,0.013692047,0.0034168707,0.0019714148,0.043320913,0.09316383],"study_design_scores_gemma":[0.041519336,0.0037269415,0.54252064,0.00027403655,0.03419297,0.00003691193,0.0044939914,0.15949684,0.0178944,0.0013320425,0.19245917,0.0020527304],"about_ca_topic_score_codex":0.00017077258,"about_ca_topic_score_gemma":0.000089084046,"teacher_disagreement_score":0.16543162,"about_ca_system_score_codex":0.00019582239,"about_ca_system_score_gemma":0.00009142317,"threshold_uncertainty_score":0.9993301},"labels":[],"label_agreement":null},{"id":"W4295905156","doi":"10.1007/s41669-022-00363-1","title":"Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); EVERSANA (Canada); Memorial University of Newfoundland; University of British Columbia; Queen's University","funders":"Novartis Pharmaceuticals Canada","keywords":"Relapsing remitting; Ofatumumab; Multiple sclerosis; Medicine; Physical medicine and rehabilitation; Internal medicine; Psychiatry","score_opus":0.22839817792887346,"score_gpt":0.41324001322696846,"score_spread":0.184841835298095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295905156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929307,0.0007107649,0.000051942297,0.0005563466,0.00017631442,0.0044718618,0.00090477994,0.000003988718,0.00019326124],"genre_scores_gemma":[0.9957838,0.0012101135,0.00022408819,0.00012349641,0.000021424026,0.0024876029,0.00007638274,0.000021980006,0.000051080668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984866,0.00018746594,0.00053707254,0.0003179531,0.00017943596,0.00029150647],"domain_scores_gemma":[0.99638194,0.0028145975,0.00028475208,0.000344133,0.0000983585,0.000076247474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010126001,0.00015091397,0.00084337476,0.00022816211,0.00021508857,0.0000149060015,0.00040748212,0.0000143884,0.00025981187],"category_scores_gemma":[0.00016722243,0.00012262385,0.00022440443,0.0005059671,0.000058644993,0.00007108253,0.00033665416,0.00011904477,3.3478838e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042145383,0.0010302223,0.7272642,0.00015579905,0.00832918,0.0000031506518,0.0019142637,0.1413922,0.022187695,0.000022588496,0.0009290761,0.09255705],"study_design_scores_gemma":[0.014640722,0.00040923452,0.63162225,0.000052280127,0.0016756773,7.918964e-7,0.0028465444,0.29978672,0.039116878,0.0000049239557,0.009657321,0.00018664158],"about_ca_topic_score_codex":0.8018033,"about_ca_topic_score_gemma":0.5834749,"teacher_disagreement_score":0.2183284,"about_ca_system_score_codex":0.0028862671,"about_ca_system_score_gemma":0.00090201915,"threshold_uncertainty_score":0.7547488},"labels":[],"label_agreement":null},{"id":"W4308254443","doi":"10.1007/s41669-022-00375-x","title":"A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Foothills Medical Centre","funders":"AbbVie","keywords":"Obinutuzumab; Venetoclax; Medicine; Chlorambucil; Rituximab; Bendamustine; Internal medicine; Fludarabine; Chronic lymphocytic leukemia; Ibrutinib; Oncology; Population; Ofatumumab; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma","score_opus":0.04922340262774139,"score_gpt":0.3689317120683685,"score_spread":0.3197083094406271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308254443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939042,0.0011180433,0.000001948829,0.00008040199,0.00009127591,0.004116302,0.00011234765,0.000008394027,0.00056710397],"genre_scores_gemma":[0.99642265,0.0009889334,0.000012782599,0.00045065157,0.000027842154,0.0018398511,0.000106023435,0.00004201836,0.00010923784],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975809,0.0002911591,0.0006828629,0.000645966,0.00027434045,0.00052477245],"domain_scores_gemma":[0.9983527,0.0007158234,0.00019322186,0.00048259806,0.000051567862,0.00020408239],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012298299,0.00025023666,0.0010599876,0.0005597911,0.000090430214,0.0000374924,0.0005993592,0.000044738357,0.0011504047],"category_scores_gemma":[0.000083136896,0.000269461,0.00009500099,0.0011690004,0.000090365735,0.00014072395,0.000767033,0.00036413237,0.00000445322],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0041151457,0.000038132614,0.0058199563,0.00030780895,0.0009008592,0.00034195074,0.00043117304,0.9822661,0.000561547,0.000112243215,0.00010699849,0.004998039],"study_design_scores_gemma":[0.043884855,0.00043209188,0.00980232,0.00006857964,0.00025560282,0.00008343171,0.00015828517,0.9405372,0.0015724162,0.00012765967,0.002817429,0.00026011356],"about_ca_topic_score_codex":0.97930264,"about_ca_topic_score_gemma":0.87436914,"teacher_disagreement_score":0.40460974,"about_ca_system_score_codex":0.7097142,"about_ca_system_score_gemma":0.30510446,"threshold_uncertainty_score":0.99997574},"labels":[],"label_agreement":null},{"id":"W4321490951","doi":"10.1007/s41669-023-00396-0","title":"Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network; Hôpital Charles-Le Moyne; William Osler Health System","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Adjuvant; Lung cancer; Oncology; Internal medicine; Quality of life (healthcare); Disease; Cost effectiveness; Quality-adjusted life year; Cancer; Epidermal growth factor receptor","score_opus":0.040697525512166634,"score_gpt":0.4178555083762873,"score_spread":0.37715798286412067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321490951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908214,0.00011728427,0.000025671827,0.00006968183,0.00013546039,0.005958301,0.00033489586,0.000009507105,0.0025277743],"genre_scores_gemma":[0.99784106,0.000044701053,0.00009234561,0.000055871933,0.000015100706,0.0012260727,0.00062835956,0.000027653508,0.00006881492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988881,0.00016731882,0.000333683,0.0002591303,0.00019035743,0.00016142041],"domain_scores_gemma":[0.99874735,0.00016948581,0.00025216385,0.00015043738,0.0006147727,0.00006578083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007992501,0.00012642135,0.00035257367,0.00018464979,0.000035767407,0.0000133044705,0.00012393082,0.000033956603,0.00015967873],"category_scores_gemma":[0.000025674131,0.00011179106,0.000037191523,0.00030492202,0.000030399022,0.0001945671,0.000063580876,0.00007907526,0.000007847606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00394994,0.0011495892,0.9150576,0.0005506785,0.0013260365,0.0000081672615,0.0031444659,0.04968358,0.0063344226,0.000021523638,0.00038973114,0.01838427],"study_design_scores_gemma":[0.02452762,0.00027973307,0.8614466,0.00039509276,0.0013206784,3.0597516e-7,0.00014170891,0.032163594,0.07955601,0.000027119442,0.000019686557,0.00012183793],"about_ca_topic_score_codex":0.0023865816,"about_ca_topic_score_gemma":0.0002427065,"teacher_disagreement_score":0.07322159,"about_ca_system_score_codex":0.00066737086,"about_ca_system_score_gemma":0.0008628453,"threshold_uncertainty_score":0.4558707},"labels":[],"label_agreement":null},{"id":"W4323921312","doi":"10.1007/s41669-023-00400-7","title":"Cost Analysis of a Transition Care Bundle Compared with Usual Care for COPD Patients Being Discharged from Hospital: Evaluation of a Randomized Controlled Trial","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary; Alberta Health; University of Alberta; Institute of Health Economics","funders":"University of Alberta; Canadian Institutes of Health Research; Alberta Innovates - Health Solutions; Alberta Health Services","keywords":"Randomized controlled trial; Medicine; COPD; Bundle; Emergency medicine; Internal medicine","score_opus":0.044061459394029855,"score_gpt":0.3905816534093894,"score_spread":0.34652019401535955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323921312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619532,0.00030758264,0.00015852743,0.00016259529,0.00022639676,0.033295367,0.0034698625,0.000022481447,0.0004039716],"genre_scores_gemma":[0.9822604,0.000047393365,0.0001506409,0.00003821365,0.00009659211,0.0053808605,0.011962673,0.00004447534,0.00001873405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971259,0.0005254087,0.0010280885,0.00049603125,0.0005402243,0.00028429553],"domain_scores_gemma":[0.99670446,0.00074398075,0.0006207827,0.00031604973,0.0014379015,0.0001768327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013673208,0.00024190122,0.0027481597,0.00046844172,0.00010739487,0.00005263151,0.000285962,0.00006347753,0.0005581055],"category_scores_gemma":[0.0002532326,0.00020609717,0.0007764514,0.00044045094,0.00014097958,0.00026832297,0.00009149237,0.000117509764,0.000005081142],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96433574,0.00068350404,0.005367922,0.000296863,0.010570016,0.0000013307993,0.009367884,0.006248087,0.00026985782,0.00002071118,0.00009782156,0.002740273],"study_design_scores_gemma":[0.7506023,0.0003043433,0.0059757684,0.000076459764,0.018168708,5.1464973e-8,0.0038032057,0.22010677,0.0007378115,0.000040068826,0.000021269181,0.00016326325],"about_ca_topic_score_codex":0.00085122744,"about_ca_topic_score_gemma":0.00017468317,"teacher_disagreement_score":0.21385868,"about_ca_system_score_codex":0.0006412166,"about_ca_system_score_gemma":0.0007228342,"threshold_uncertainty_score":0.84043986},"labels":[],"label_agreement":null},{"id":"W4360601194","doi":"10.1007/s41669-023-00406-1","title":"Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis","keywords":"Purchasing; Discounting; Health care; Thematic analysis; Value-Based Purchasing; Business; Reimbursement; Actuarial science; Public economics; Marketing; Economics; Qualitative research; Economic growth; Finance","score_opus":0.5573958734861583,"score_gpt":0.5653476281504209,"score_spread":0.007951754664262678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360601194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6852817,0.0026268507,0.00033542924,0.30732977,0.00054674275,0.0023174596,0.0006234201,0.000048045058,0.0008905825],"genre_scores_gemma":[0.97665477,0.006719057,0.0033187293,0.012024887,0.00034640354,0.00046864428,0.00006990724,0.000046725825,0.00035086492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957008,0.00056630856,0.002453448,0.00084765785,0.00007477941,0.00035702545],"domain_scores_gemma":[0.9933649,0.0033072797,0.002485841,0.00059768866,0.00011070995,0.00013359061],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016216623,0.00021871863,0.00091794855,0.00026404066,0.00034891348,0.00018362589,0.00073954475,0.00010024776,0.0006787314],"category_scores_gemma":[0.0012220633,0.0002236309,0.00005769156,0.00016076799,0.00016039815,0.00083936827,0.00033658257,0.00028389113,0.0011472746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038305766,0.00072310976,0.4242747,0.0012493406,0.0011080849,0.000004733523,0.09019208,0.0019393691,0.0005415409,0.3519782,0.12294501,0.0046607493],"study_design_scores_gemma":[0.0070223296,0.0010091071,0.5786026,0.0007856156,0.00011198701,0.000009108713,0.056502752,0.11227236,0.0017142369,0.017973533,0.22219197,0.001804404],"about_ca_topic_score_codex":0.0035978062,"about_ca_topic_score_gemma":0.00023596454,"teacher_disagreement_score":0.33400467,"about_ca_system_score_codex":0.0012101516,"about_ca_system_score_gemma":0.0005753728,"threshold_uncertainty_score":0.99963045},"labels":[],"label_agreement":null},{"id":"W4364376102","doi":"10.1007/s41669-023-00409-y","title":"Economic Evaluation Comparing Virtual Reality with Child Life Programming for Non-sedated Pediatric Medical Imaging: A Cost-Consequence Analysis","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; BC Children's Hospital; University of British Columbia","funders":"Mitacs","keywords":"Virtual reality; Psychology; Computer science; Human–computer interaction","score_opus":0.06749193653518161,"score_gpt":0.4162319603709268,"score_spread":0.3487400238357452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364376102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537786,0.00008278779,0.020275874,0.009285989,0.00029530484,0.011213985,0.00011408661,0.0007472955,0.004206045],"genre_scores_gemma":[0.9920252,0.0004643696,0.0014652367,0.0016747442,0.00061804923,0.002385371,0.0012376624,0.000060132465,0.000069209396],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99730605,0.00014459086,0.0007974462,0.00085030776,0.00033062548,0.00057097943],"domain_scores_gemma":[0.9980739,0.0003017855,0.00045486316,0.0005353318,0.00014094163,0.0004931801],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0057021547,0.00030470514,0.00082429015,0.0008222335,0.00021827291,0.00024675296,0.0008365461,0.00008347872,0.0002794022],"category_scores_gemma":[0.00029261367,0.00031279307,0.0001865268,0.0008357051,0.00010108788,0.00054932135,0.0004868118,0.000299906,0.00010115127],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016386035,0.000337958,0.89974266,0.0002654941,0.0031557954,0.000119924945,0.00026799607,0.011026581,0.00003107232,0.000279035,0.049400557,0.033734307],"study_design_scores_gemma":[0.006348332,0.00010155454,0.046021108,0.0000297016,0.004842091,0.000022655295,0.00012734141,0.9364297,0.00009205715,0.00011789681,0.0054213507,0.0004462471],"about_ca_topic_score_codex":0.0007486856,"about_ca_topic_score_gemma":0.00023156153,"teacher_disagreement_score":0.92540306,"about_ca_system_score_codex":0.0006228565,"about_ca_system_score_gemma":0.0010143631,"threshold_uncertainty_score":0.9999324},"labels":[],"label_agreement":null},{"id":"W4366351945","doi":"10.1007/s41669-023-00407-0","title":"Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Osimertinib; Medicine; Lung cancer; Health care; Population; Oncology; Disease; Internal medicine; Chemotherapy; Cancer; Intensive care medicine; Epidermal growth factor receptor; Erlotinib; Environmental health","score_opus":0.041307286050652516,"score_gpt":0.38080286673296865,"score_spread":0.3394955806823161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366351945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942242,0.0002026571,0.00004641763,0.0017856894,0.00003713007,0.0031313938,0.0004520225,0.000028897233,0.000091593065],"genre_scores_gemma":[0.99231577,0.0012299829,0.0001522159,0.0011879525,0.000013167258,0.0008379715,0.0041626017,0.000036343023,0.00006399913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986684,0.00014258333,0.00035340237,0.00045319053,0.00008896483,0.00029349205],"domain_scores_gemma":[0.99920774,0.00012824697,0.00018025233,0.00024622885,0.00010692485,0.00013060823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021625338,0.00022506708,0.00038832173,0.00047922437,0.00015444028,0.00008392028,0.00015864841,0.000042665037,0.000023204919],"category_scores_gemma":[0.000005799835,0.0001671505,0.00003359868,0.0014276326,0.000030985135,0.00025083066,0.000035046953,0.0001269125,0.0000018373498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012394422,0.00044709689,0.82892287,0.00005957716,0.00028995436,0.000019204628,0.008741718,0.15141639,0.000006100652,0.0000014931566,0.00004842103,0.008807746],"study_design_scores_gemma":[0.017015189,0.0005737666,0.7739607,0.00018848866,0.00060829986,3.1527568e-7,0.002416008,0.20396285,0.00022495344,0.0000042674537,0.00084300514,0.0002021343],"about_ca_topic_score_codex":0.01934001,"about_ca_topic_score_gemma":0.03413394,"teacher_disagreement_score":0.054962132,"about_ca_system_score_codex":0.0014814337,"about_ca_system_score_gemma":0.00026677817,"threshold_uncertainty_score":0.9871903},"labels":[],"label_agreement":null},{"id":"W4367175132","doi":"10.1007/s41669-023-00415-0","title":"Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Systematic review; Medicine; Critical appraisal; Checklist; Grey literature; MEDLINE; Nephropathy; Quality of life (healthcare); Economic evaluation; Health care; Family medicine; Intensive care medicine; Alternative medicine; Psychology; Nursing; Pathology; Political science","score_opus":0.08089463607554481,"score_gpt":0.4101879574652315,"score_spread":0.3292933213896867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367175132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018033746,0.9923252,6.948558e-7,0.00009634909,0.00021364141,0.005948135,0.0006793257,0.000029744946,0.00052656245],"genre_scores_gemma":[0.00009901653,0.9971983,0.000083932864,0.00010515821,0.00032276876,0.0011570463,0.00014162286,0.000106157335,0.00078601355],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99703157,0.00035915052,0.0016263023,0.0006659663,0.00006583468,0.00025115383],"domain_scores_gemma":[0.9973343,0.0006122963,0.0012400282,0.00048810922,0.000043421212,0.00028182621],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009577875,0.00058943697,0.0051745195,0.00027975035,0.00013067968,0.00033509682,0.00039809343,0.00017513595,0.00012921612],"category_scores_gemma":[0.00023345782,0.00044545266,0.0004240108,0.00011450391,0.00013214193,0.000254241,0.0005122064,0.0003067663,0.00018707439],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004100122,0.00002649229,0.000004148345,0.9413848,0.0011335749,0.000058274272,0.0010961324,0.0000011432182,0.0000020590244,0.00043778762,0.0037151224,0.05209945],"study_design_scores_gemma":[0.0006305608,0.00009986163,0.000006838437,0.4794076,0.010304392,0.00027869898,0.00031494812,0.00030178367,0.0000031131449,0.00013222615,0.5078721,0.00064784114],"about_ca_topic_score_codex":0.0000872841,"about_ca_topic_score_gemma":0.000007480425,"teacher_disagreement_score":0.504157,"about_ca_system_score_codex":0.00016353156,"about_ca_system_score_gemma":0.00029547434,"threshold_uncertainty_score":0.9997997},"labels":[],"label_agreement":null},{"id":"W4378745433","doi":"10.1007/s41669-023-00422-1","title":"Perceptions and Attitudes Regarding Medical Device Development in Canada Among Canadian Innovators: A Qualitative Study","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; Institute of Health Economics; University of Calgary; University of British Columbia","funders":"","keywords":"Perception; Focus group; Qualitative research; Process (computing); Health technology; Marketing; Psychology; Public relations; Health care; Business; Medical education; Medicine; Political science; Sociology; Economic growth; Economics","score_opus":0.3893493514127117,"score_gpt":0.5220560011702162,"score_spread":0.1327066497575045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378745433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981149,0.0001283799,0.000013306591,0.013244867,0.00050745846,0.0015992618,0.00021729278,0.00002946765,0.0031109636],"genre_scores_gemma":[0.98957413,0.00008327556,0.0003286502,0.008870145,0.000106700485,0.000558556,0.00007835918,0.00004569461,0.00035451446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99446315,0.0004923355,0.0034189618,0.00081987615,0.00011862685,0.00068708026],"domain_scores_gemma":[0.9972487,0.0008940118,0.00076357444,0.00033840755,0.000056605968,0.00069869024],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.023660373,0.00025868564,0.0009791043,0.00075170904,0.00039856724,0.0002585297,0.00082121155,0.00009278311,0.0013153487],"category_scores_gemma":[0.0010796291,0.00035825404,0.00003162804,0.0005066046,0.00006201149,0.0009148697,0.00040272882,0.00034430338,0.00093192013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000011086542,0.00007564327,0.9154926,0.00010297628,0.00023707256,0.000021137825,0.0571605,0.00025990856,5.2322144e-7,0.003863126,0.022266833,0.00050861144],"study_design_scores_gemma":[0.003275771,0.00003637497,0.76021296,0.00015026865,0.000011739417,0.000006496078,0.1509772,0.010826311,0.0000040814302,0.0008745285,0.072616085,0.0010082042],"about_ca_topic_score_codex":0.9942843,"about_ca_topic_score_gemma":0.9991718,"teacher_disagreement_score":0.15527964,"about_ca_system_score_codex":0.0051645227,"about_ca_system_score_gemma":0.006048036,"threshold_uncertainty_score":0.99988693},"labels":[],"label_agreement":null},{"id":"W4382139156","doi":"10.1007/s41669-023-00427-w","title":"Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Blood transfusion and management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; University of Alberta; Alberta Environment and Protected Areas","funders":"","keywords":"Dosing; Platelet transfusion; Platelet; Medicine; Selection (genetic algorithm); Blood preservation; Blood transfusion; Intensive care medicine; Pharmacology; Computer science; Internal medicine; Andrology; Machine learning","score_opus":0.1402910018837543,"score_gpt":0.49555661481741897,"score_spread":0.35526561293366465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382139156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002389962,0.9667096,0.00069928507,0.000057864203,0.00030422895,0.03155201,0.000044808297,0.000052262312,0.0003409601],"genre_scores_gemma":[0.00004113532,0.9953274,0.00048384568,0.00017915465,0.000033789645,0.0035377727,0.00018392963,0.00009481813,0.000118112424],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99547815,0.0016984199,0.0017451034,0.0006873054,0.00013101079,0.00026002538],"domain_scores_gemma":[0.9979788,0.0008438479,0.0006095645,0.000357286,0.00005647777,0.00015400148],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004016884,0.00051284244,0.005097991,0.00040905442,0.00007108689,0.000078427176,0.00033441558,0.00018045012,0.00012472775],"category_scores_gemma":[0.000074079464,0.00041506434,0.00033495217,0.00043657408,0.000029667906,0.00018035038,0.00019532951,0.00045729955,0.000021704647],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001470691,0.00016874379,0.0000016614097,0.8986957,0.0009552385,0.000017134655,0.000092997994,0.000008423819,0.000019298532,0.000091155875,0.00011188888,0.099690706],"study_design_scores_gemma":[0.0039564837,0.0001950073,0.000010822856,0.8722098,0.008785123,0.00019150459,0.000025542286,0.0006313125,0.00027399985,0.000032305867,0.113147475,0.0005406432],"about_ca_topic_score_codex":0.00012351936,"about_ca_topic_score_gemma":0.00007276214,"teacher_disagreement_score":0.11303558,"about_ca_system_score_codex":0.00034666675,"about_ca_system_score_gemma":0.00019388067,"threshold_uncertainty_score":0.9998301},"labels":[],"label_agreement":null},{"id":"W4387077281","doi":"10.1007/s41669-023-00441-y","title":"Estimating Cumulative Health Care Costs of Childhood and Adolescence Autism Spectrum Disorder in Ontario, Canada: A Population-Based Incident Cohort Study","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Autism Spectrum Disorder Research","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Rehabilitation Institute; Institute for Clinical Evaluative Sciences; Centre for Addiction and Mental Health","funders":"","keywords":"Cumulative incidence; Medicine; Inverse probability weighting; Health care; Population; Cohort; Demography; Pediatrics; Incidence (geometry); Autism spectrum disorder; Propensity score matching; Autism; Environmental health; Psychiatry; Surgery; Internal medicine","score_opus":0.030199127256097448,"score_gpt":0.354877130522664,"score_spread":0.32467800326656654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387077281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918404,0.000037945952,0.000024969599,0.0035782382,0.00017622884,0.00395511,0.00008589547,0.000033737404,0.00026745893],"genre_scores_gemma":[0.99898195,0.000012023963,0.000116910094,0.0005838352,0.000008814686,0.00017467413,0.000044125805,0.00003839648,0.00003924226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974313,0.00028833438,0.0006517949,0.00076647487,0.00031461578,0.00054748665],"domain_scores_gemma":[0.9988996,0.00025942607,0.0003289772,0.0003211994,0.0000072489793,0.00018357308],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000623053,0.00023076909,0.00049606524,0.0002434693,0.0002761982,0.00012249681,0.00071627914,0.000028628705,0.0001720245],"category_scores_gemma":[0.000090189336,0.0002663181,0.000028255165,0.00042508318,0.00005055397,0.00034789808,0.0006763083,0.00040140375,0.000009612661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004260502,0.00017885862,0.9709779,0.000026255402,0.000011637099,0.000017761942,0.003434208,0.023920106,0.000018715686,0.0005076266,0.000046731715,0.0008175766],"study_design_scores_gemma":[0.0019415339,0.00009671774,0.9429462,0.00005438403,0.0000074299373,0.0000018877137,0.00045681847,0.053676303,0.00020449891,0.0003739974,0.000014871487,0.00022535796],"about_ca_topic_score_codex":0.9939705,"about_ca_topic_score_gemma":0.99699455,"teacher_disagreement_score":0.029756196,"about_ca_system_score_codex":0.0025120208,"about_ca_system_score_gemma":0.0028360102,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W4387530829","doi":"10.1007/s41669-023-00444-9","title":"Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health Research Institute; Vancouver Coastal Health; Canadian Centre for Applied Research in Cancer Control; University of British Columbia; Simon Fraser University; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Genome British Columbia; Canadian Cancer Society; Canadian Centre for Applied Research in Cancer Control; Genome Canada","keywords":"Panitumumab; Cetuximab; KRAS; Colorectal cancer; Medicine; Oncology; Internal medicine; Family medicine; Cancer","score_opus":0.09380784200263412,"score_gpt":0.4210999267675946,"score_spread":0.3272920847649605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387530829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157447,0.00011492333,0.0000012239743,0.00025979243,0.00013871882,0.004380675,0.0020131029,0.000011257865,0.0015058136],"genre_scores_gemma":[0.99669605,0.0007059294,0.00022421729,0.00021200073,0.000039492,0.0016034405,0.00004816978,0.000030530253,0.00044015746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871784,0.00004210674,0.00060352054,0.0002414355,0.000107116,0.00028795],"domain_scores_gemma":[0.99824494,0.001023494,0.00027941473,0.00011510357,0.00023948852,0.000097554104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004893548,0.00013650891,0.00097102456,0.0001470755,0.00006558051,0.000030683572,0.00021400803,0.000019403233,0.000081298844],"category_scores_gemma":[0.0002158797,0.00016001739,0.000067572706,0.0008027112,0.000054392352,0.00010383942,0.00017428363,0.000072521565,5.49319e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022027351,0.0011780569,0.6726588,0.0029990573,0.003591592,0.00009713943,0.0022934147,0.0026501846,0.020875998,0.00006404094,0.0055287303,0.26603562],"study_design_scores_gemma":[0.026787829,0.0024282085,0.9151879,0.00093470415,0.00024911945,0.000012227289,0.00077651424,0.002338211,0.04758315,0.0001618226,0.0031732975,0.0003670022],"about_ca_topic_score_codex":0.9775838,"about_ca_topic_score_gemma":0.9907181,"teacher_disagreement_score":0.26566863,"about_ca_system_score_codex":0.0009976163,"about_ca_system_score_gemma":0.0030732928,"threshold_uncertainty_score":0.652532},"labels":[],"label_agreement":null},{"id":"W4388790771","doi":"10.1007/s41669-023-00453-8","title":"Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Confidence interval; Incidence (geometry); Intensive care unit; Pediatrics; Emergency medicine; Diagnosis code; Internal medicine; Population","score_opus":0.034491389858649295,"score_gpt":0.32302525963155976,"score_spread":0.28853386977291046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388790771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995637,0.000040499377,2.2277837e-7,0.0011570551,0.00018806892,0.0014332618,0.00025706162,0.000030206875,0.0012566032],"genre_scores_gemma":[0.99783224,0.00045806245,0.000108195614,0.0003470296,0.00008690109,0.00020506357,0.00064845866,0.000045711855,0.0002683573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986055,0.00004029879,0.000416107,0.00043014652,0.00012389872,0.0003840386],"domain_scores_gemma":[0.9991317,0.000105710096,0.00012130648,0.00032966607,0.00006107672,0.00025056658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002128104,0.00020153468,0.000556425,0.0002907389,0.000057253375,0.000032040578,0.00030977913,0.000061639985,0.0006608179],"category_scores_gemma":[0.000016279624,0.0001685326,0.0000699568,0.00015308025,0.00005951481,0.00033706552,0.00034459468,0.00013752705,0.00058507506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014401582,0.002037315,0.94753873,0.00007220899,0.00067133846,0.0016249173,0.00008015369,0.00073683576,0.0024534792,0.000028212611,0.016712122,0.013643088],"study_design_scores_gemma":[0.026228879,0.0012502965,0.9460457,0.000165865,0.00020709864,0.00006128863,0.00011271721,0.013377192,0.003572998,0.00021199572,0.00832039,0.00044560476],"about_ca_topic_score_codex":0.0016171309,"about_ca_topic_score_gemma":0.000040781102,"teacher_disagreement_score":0.0131974835,"about_ca_system_score_codex":0.0001775917,"about_ca_system_score_gemma":0.0001948077,"threshold_uncertainty_score":0.7520151},"labels":[],"label_agreement":null},{"id":"W4390706466","doi":"10.1007/s41669-023-00464-5","title":"A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Quality of life (healthcare); Population; Rituximab; Health care; Systematic review; MEDLINE; Oncology; Family medicine; Lymphoma; Internal medicine; Environmental health; Cancer; Immunotherapy; Nursing","score_opus":0.13180303865277276,"score_gpt":0.47445124690915247,"score_spread":0.3426482082563797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390706466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027533253,0.98594123,1.3747591e-7,0.00035241712,0.00021137117,0.009074445,0.0009377258,0.000026558639,0.0007027847],"genre_scores_gemma":[0.0005637765,0.9945741,0.000025925889,0.0007163079,0.0000197285,0.00029118147,0.00036028432,0.000102608494,0.0033460797],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9897941,0.003585661,0.0050771674,0.00080142723,0.0002995402,0.00044215113],"domain_scores_gemma":[0.9943745,0.0016384445,0.0027010494,0.00079655286,0.00016726027,0.00032217792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.015975345,0.0006039624,0.0099023245,0.00042522646,0.0000482355,0.00008796591,0.00056726206,0.00041486666,0.00059589325],"category_scores_gemma":[0.0014601467,0.00042723195,0.00062004564,0.00059555663,0.00010950529,0.00015483447,0.0006862534,0.0008975699,0.000017103608],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020984186,0.0006834105,0.00018863477,0.96227574,0.0015413911,0.000021966409,0.00046512584,9.903974e-9,0.0000030324945,0.000021642505,0.0014565353,0.03313269],"study_design_scores_gemma":[0.007880236,0.00023362949,0.00026984673,0.9194572,0.0023187015,0.00003848463,0.000081975966,0.00009557559,0.0000029952666,0.00004667323,0.069112465,0.00046220177],"about_ca_topic_score_codex":0.00036565738,"about_ca_topic_score_gemma":0.00004070584,"teacher_disagreement_score":0.06765593,"about_ca_system_score_codex":0.00067879516,"about_ca_system_score_gemma":0.0020548766,"threshold_uncertainty_score":0.99981797},"labels":[],"label_agreement":null},{"id":"W4393183309","doi":"10.1007/s41669-024-00481-y","title":"A Canadian Simulation Model for Major Depressive Disorder: Study Protocol","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Treatment of Major Depression","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Health; University of British Columbia; BC Centre for Disease Control; Vancouver Coastal Health; Vancouver Coastal Health Research Institute; Simon Fraser University","funders":"Genome British Columbia; Michael Smith Health Research BC; Genome Canada","keywords":"Major depressive disorder; Psychological intervention; Flexibility (engineering); Protocol (science); Depression (economics); Quality of life (healthcare); Health care; Microsimulation; Medicine; Economic evaluation; Psychiatry; Alternative medicine; Engineering; Nursing","score_opus":0.05893575928001667,"score_gpt":0.44301641223820665,"score_spread":0.38408065295819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393183309","genre_codex":"protocol","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20833196,0.00015793304,0.004740649,0.005349111,0.0004504811,0.7719942,0.00047228477,0.00027020773,0.00823323],"genre_scores_gemma":[0.76003146,0.0000020069829,0.0008989214,0.00048190297,0.00012469535,0.23461248,0.00006963072,0.00007098452,0.003707903],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9987486,0.000027685835,0.0003171889,0.0005251561,0.000078202385,0.0003031953],"domain_scores_gemma":[0.99916214,0.00010770836,0.00006242997,0.00029823428,0.00005066131,0.00031880153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022435257,0.00021339205,0.0002918681,0.0001824199,0.00017313423,0.00028850653,0.0002853926,0.0000590406,0.0003414623],"category_scores_gemma":[0.000022698094,0.00018887449,0.00009176261,0.00006446184,0.000012426882,0.00049170176,0.00014826312,0.00013502235,0.00012290914],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008394682,0.0041724467,0.105972365,0.0014810081,0.0033014093,0.00036664086,0.0059547625,0.57914716,0.0015976575,0.00086216116,0.061702702,0.227047],"study_design_scores_gemma":[0.010405334,0.00023334069,0.00081662013,0.00006550676,0.00034022244,0.0000053263584,0.000057313104,0.93796283,0.0003933925,0.00053352275,0.048984475,0.00020213527],"about_ca_topic_score_codex":0.016381593,"about_ca_topic_score_gemma":0.024247672,"teacher_disagreement_score":0.5516995,"about_ca_system_score_codex":0.00054848904,"about_ca_system_score_gemma":0.00073168526,"threshold_uncertainty_score":0.9935573},"labels":[],"label_agreement":null},{"id":"W4394713652","doi":"10.1007/s41669-024-00483-w","title":"Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline Biologicals","keywords":"Medicine; Cost effectiveness; Quality-adjusted life year; Cost-effectiveness analysis; Vaccination; Vaccine efficacy; Demography; Public health; Economic evaluation; Cost–benefit analysis; Health care; Pediatrics; Virology; Economics","score_opus":0.0365584503831496,"score_gpt":0.3928126937570696,"score_spread":0.35625424337392003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394713652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566305,0.00083380303,0.0000015166601,0.0010900338,0.00024385986,0.0015037694,0.00010999891,0.000011634436,0.0005423417],"genre_scores_gemma":[0.9985651,0.0007442236,0.000024887364,0.0003492067,0.000014455368,0.000064424275,0.00012259658,0.000024820481,0.000090321715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990726,0.00010934635,0.00023827663,0.0002687912,0.00002481708,0.00028614447],"domain_scores_gemma":[0.99931604,0.00007197635,0.000042040097,0.00012020453,0.000016992828,0.00043271997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079111697,0.00012459642,0.0003522145,0.00029446185,0.00004304703,0.000103385,0.000060054004,0.000043179927,0.00035284043],"category_scores_gemma":[0.000009731475,0.00011054797,0.000031059204,0.00013256392,0.000017868186,0.00026352366,0.00006561494,0.0001455559,0.000018453065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006239607,0.00034737162,0.70832837,0.00049757713,0.00072386337,0.0001450232,0.0009357444,0.000009950049,0.00014710866,0.00009690494,0.0036982305,0.28444588],"study_design_scores_gemma":[0.008690431,0.00025023532,0.92523235,0.00039950229,0.000049862414,0.00009078121,0.000035150297,0.0015447793,0.0001796948,0.000039879764,0.06334163,0.00014570159],"about_ca_topic_score_codex":0.38443607,"about_ca_topic_score_gemma":0.11569297,"teacher_disagreement_score":0.28430018,"about_ca_system_score_codex":0.00058760034,"about_ca_system_score_gemma":0.0006447862,"threshold_uncertainty_score":0.9004433},"labels":[],"label_agreement":null},{"id":"W4396576727","doi":"10.1007/s41669-024-00484-9","title":"Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Lung cancer; Quality of life (healthcare); EQ-5D; Medicine; Construct validity; Cancer; Physical therapy; Disease; Psychometrics; Clinical psychology; Health related quality of life; Oncology; Nursing; Internal medicine","score_opus":0.7914805543456943,"score_gpt":0.5302336988651476,"score_spread":0.2612468554805467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396576727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7935886,0.16208464,0.00011896408,0.010776614,0.0058090375,0.012328464,0.01470241,0.00003575857,0.0005555238],"genre_scores_gemma":[0.98933554,0.005746566,0.00014594736,0.0022973977,0.0004039396,0.0016705288,0.000257829,0.00007616871,0.00006610531],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9890141,0.0013540299,0.007463529,0.0011814075,0.00042349662,0.000563426],"domain_scores_gemma":[0.993307,0.0007017427,0.0043974477,0.0011153936,0.00033041785,0.00014803185],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.050331075,0.00037743346,0.0020474107,0.0003046005,0.00022053381,0.00025958245,0.0018305593,0.00014226299,0.001541841],"category_scores_gemma":[0.0016720062,0.0003784542,0.0001812637,0.00028724803,0.00011530062,0.0013466225,0.0006338096,0.00038999875,0.00005153391],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000939996,0.0012615459,0.679796,0.011297503,0.0035654923,9.131571e-7,0.033117928,0.038050093,0.00032012427,0.0072084377,0.20395036,0.020491607],"study_design_scores_gemma":[0.0067110457,0.000031674554,0.025653144,0.003218227,0.0002465981,3.785659e-7,0.002952355,0.8797244,0.00028655308,0.0010595039,0.079416074,0.000700078],"about_ca_topic_score_codex":0.076634966,"about_ca_topic_score_gemma":0.014889804,"teacher_disagreement_score":0.84167427,"about_ca_system_score_codex":0.0055843396,"about_ca_system_score_gemma":0.0031128963,"threshold_uncertainty_score":0.9998667},"labels":[],"label_agreement":null},{"id":"W4400731480","doi":"10.1007/s41669-024-00502-w","title":"Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older","year":2024,"lang":"en","type":"erratum","venue":"PharmacoEconomics - Open","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Public health; Recombinant DNA; Gerontology; Environmental health; Nursing; Biology; Genetics","score_opus":0.03135076596778646,"score_gpt":0.37623301049223784,"score_spread":0.3448822445244514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400731480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93386847,0.006075097,0.000001699486,0.0023404749,0.034869254,0.0074393726,0.0009889728,0.000048672708,0.014368014],"genre_scores_gemma":[0.9675422,0.0073739463,0.000018104376,0.0008013439,0.00024662784,0.0003093337,0.0026711768,0.00014319905,0.020894077],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981459,0.00021985569,0.00050275197,0.00058545184,0.000057214962,0.000488871],"domain_scores_gemma":[0.9986851,0.00009038423,0.00019446964,0.00026164588,0.000052964417,0.0007153967],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010454408,0.00034121887,0.0009909727,0.00069183245,0.00008572211,0.00018184006,0.00013282915,0.00023578659,0.0006404344],"category_scores_gemma":[0.000025887786,0.00032018515,0.000083537074,0.00023041097,0.000035201498,0.00024624154,0.00016678388,0.00079920026,0.000039515082],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000635714,0.00034331545,0.0686402,0.0008995959,0.0012010029,0.00014851982,0.000458911,0.0000038031642,0.0000044381086,0.000007885395,0.8363147,0.091341935],"study_design_scores_gemma":[0.00763746,0.00036793703,0.28254336,0.0015351932,0.00016922747,0.00019876541,0.000039381743,0.00091026473,0.00001637878,0.0000175167,0.7062708,0.00029368885],"about_ca_topic_score_codex":0.55370677,"about_ca_topic_score_gemma":0.34494823,"teacher_disagreement_score":0.21390314,"about_ca_system_score_codex":0.0017833087,"about_ca_system_score_gemma":0.002546739,"threshold_uncertainty_score":0.999925},"labels":[],"label_agreement":null},{"id":"W4401109065","doi":"10.1007/s41669-024-00513-7","title":"Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Novocure; Gilead Sciences","keywords":"Antiretroviral therapy; Cost effectiveness; Cohort; Medicine; Human immunodeficiency virus (HIV); Intensive care medicine; Risk analysis (engineering); Viral load; Internal medicine; Virology","score_opus":0.12949161976690404,"score_gpt":0.5175589457037367,"score_spread":0.3880673259368327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401109065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818187,0.0010063407,0.000114097915,0.00005068902,0.0001441522,0.011661777,0.00014614187,0.000042718526,0.005015421],"genre_scores_gemma":[0.99620724,0.00029563965,0.000055548073,0.000055892,0.000085681844,0.0014851653,0.000068127054,0.00005422632,0.0016924544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767226,0.0008563948,0.0004069825,0.0005534272,0.00019808425,0.00031283745],"domain_scores_gemma":[0.9985126,0.0007903898,0.00007784698,0.00028795414,0.00012825991,0.00020289952],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047175284,0.00022104704,0.00063640904,0.000221245,0.000109618784,0.00025027222,0.00030131446,0.0000515139,0.0015352686],"category_scores_gemma":[0.00011388302,0.00019605411,0.00016263036,0.00020549541,0.00011396261,0.0005459237,0.0003435395,0.00032203653,0.00012818511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006581699,0.0021382945,0.4167054,0.0013328303,0.00378497,0.00008937436,0.0006886638,0.00008475045,0.20757875,0.00026368044,0.0041765114,0.35657507],"study_design_scores_gemma":[0.035744417,0.025778446,0.59994143,0.0022707277,0.0009980347,0.000106681146,0.00036745553,0.22893159,0.09357323,0.00037865055,0.011023333,0.0008860162],"about_ca_topic_score_codex":0.0008248948,"about_ca_topic_score_gemma":0.00000957362,"teacher_disagreement_score":0.35568905,"about_ca_system_score_codex":0.0002538138,"about_ca_system_score_gemma":0.00028370426,"threshold_uncertainty_score":0.9993775},"labels":[],"label_agreement":null},{"id":"W4401322712","doi":"10.1007/s41669-024-00511-9","title":"Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact; McMaster University Medical Centre","funders":"","keywords":"Reimbursement; Agency (philosophy); Health technology; Business; Medicine; Health care; Sociology; Economic growth; Economics; Social science","score_opus":0.5233009372616017,"score_gpt":0.6065075666626815,"score_spread":0.08320662940107981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401322712","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38475528,0.0069891796,0.0036959727,0.59539294,0.00057751813,0.0049017207,0.0034333505,0.000045989804,0.00020807493],"genre_scores_gemma":[0.947844,0.001948404,0.030539604,0.017836308,0.00008829238,0.0014343611,0.00022860638,0.00003650242,0.000043882294],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947864,0.0002777657,0.00313393,0.0011218358,0.00004353536,0.00063657435],"domain_scores_gemma":[0.9952506,0.0030222905,0.00086691283,0.00034034404,0.000025087871,0.000494777],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010553956,0.0002710765,0.0017566952,0.0011906972,0.00028113485,0.00015209096,0.00035677425,0.00020732512,0.00006162217],"category_scores_gemma":[0.000890232,0.00030920783,0.000040847463,0.00019463195,0.00008839429,0.00025520177,0.0002039706,0.00042929355,0.0000038193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014435349,0.0002451202,0.45549744,0.0023968923,0.0008931512,0.000035527046,0.016672673,0.00075336127,0.000027108283,0.02632042,0.33345172,0.16356222],"study_design_scores_gemma":[0.0023676122,0.00068028993,0.19644256,0.0005091355,0.000045108136,0.000020098601,0.022244263,0.020412887,0.000199501,0.12066597,0.635329,0.0010835509],"about_ca_topic_score_codex":0.9170325,"about_ca_topic_score_gemma":0.9431164,"teacher_disagreement_score":0.5775566,"about_ca_system_score_codex":0.004522339,"about_ca_system_score_gemma":0.0038708907,"threshold_uncertainty_score":0.999936},"labels":[],"label_agreement":null},{"id":"W4402602582","doi":"10.1007/s41669-024-00522-6","title":"Publisher Correction: Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison Between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses","year":2024,"lang":"en","type":"erratum","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact; McMaster University Medical Centre","funders":"","keywords":"Agency (philosophy); Medicine; Engineering ethics; Engineering; Sociology; Social science","score_opus":0.47457637957924936,"score_gpt":0.5833406924088185,"score_spread":0.10876431282956911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402602582","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015086599,0.019759864,0.0019917754,0.917473,0.023043757,0.01224672,0.0076142196,0.000099986144,0.002684068],"genre_scores_gemma":[0.5268477,0.044572435,0.13088107,0.22822313,0.003900919,0.028453786,0.014237408,0.0008254752,0.022058055],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.991769,0.0004381513,0.0049287206,0.0018751603,0.00007947596,0.0009095021],"domain_scores_gemma":[0.9934374,0.0028050956,0.0023955181,0.0005851829,0.0000632414,0.00071358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013223875,0.00052658847,0.0033034473,0.002186701,0.0004074858,0.0003462867,0.0006363826,0.00069068465,0.00011189763],"category_scores_gemma":[0.0018461937,0.00061584706,0.000078387005,0.0003010361,0.00013112708,0.00035988181,0.00040387994,0.0014119553,0.000005617309],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000020675727,0.000039265044,0.014429431,0.0005012129,0.0002017679,0.0000048889797,0.0014042925,0.000046617683,1.7838539e-7,0.0005583575,0.9729122,0.009881133],"study_design_scores_gemma":[0.00083383615,0.00028745976,0.020366454,0.00038313525,0.00003753845,0.000010216762,0.008731913,0.003075628,0.000004727842,0.031064045,0.9345841,0.000620965],"about_ca_topic_score_codex":0.9464158,"about_ca_topic_score_gemma":0.97549677,"teacher_disagreement_score":0.6892499,"about_ca_system_score_codex":0.009441203,"about_ca_system_score_gemma":0.00999095,"threshold_uncertainty_score":0.99962926},"labels":[],"label_agreement":null},{"id":"W4403226544","doi":"10.1007/s41669-024-00523-5","title":"Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Population Health Research Institute; Takeda (Canada)","funders":"Takeda Canada","keywords":"Vedolizumab; Ulcerative colitis; Crohn's disease; Medicine; Disease; Inflammatory bowel disease; Gastroenterology; Internal medicine; Dermatology","score_opus":0.06370502091376154,"score_gpt":0.37473293745155084,"score_spread":0.3110279165377893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403226544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972976,0.00043304445,0.000024043036,0.000037193888,0.00009391441,0.0015959305,0.0004895301,0.0000035759263,0.00002516391],"genre_scores_gemma":[0.999156,0.00033059123,0.000027618118,0.00010891567,0.00005369265,0.00017085885,0.00012837023,0.000017902963,0.000006072691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810576,0.000692985,0.00035789603,0.0005763338,0.000060489892,0.00020650831],"domain_scores_gemma":[0.9991048,0.00028681022,0.000099722776,0.0003247455,0.000046132005,0.00013776553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008531285,0.00018750002,0.0003170295,0.00010127489,0.00007388481,0.00011561594,0.00042400544,0.00003031272,0.000050637605],"category_scores_gemma":[0.00008076673,0.00016669532,0.00005301737,0.00021748824,0.00006897173,0.00005373862,0.00037145658,0.00011701156,0.0000010456149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027276978,0.000067538465,0.9100517,0.000065171625,0.0004393019,0.0006157869,0.00058022793,0.08272323,0.0023485678,0.00002129597,0.000009208451,0.00035027406],"study_design_scores_gemma":[0.00084126665,0.000038847174,0.9193016,0.00012299027,0.00028602564,6.096728e-7,0.00051058474,0.076982774,0.0016348303,0.00007416883,0.00001412047,0.0001921594],"about_ca_topic_score_codex":0.87578344,"about_ca_topic_score_gemma":0.9776581,"teacher_disagreement_score":0.10187465,"about_ca_system_score_codex":0.0010029423,"about_ca_system_score_gemma":0.0022569236,"threshold_uncertainty_score":0.6797638},"labels":[],"label_agreement":null},{"id":"W4404514253","doi":"10.1007/s41669-024-00538-y","title":"Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Sepsis Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hospital Edmonton; University of Calgary; University of Alberta Hospital; Alberta Health; Foothills Medical Centre; Institute of Health Economics; University of Alberta; Alberta Energy; Alberta Health Services","funders":"bioMérieux; Alberta Innovates; Alberta Health Services","keywords":"Medicine; Antimicrobial stewardship; Procalcitonin; Cost effectiveness; Emergency medicine; Blood culture; Intensive care unit; Sepsis; Cost-effectiveness analysis; Health care; Intensive care medicine; Internal medicine; Antibiotic resistance; Antibiotics","score_opus":0.1367678741257744,"score_gpt":0.4476165044249941,"score_spread":0.3108486302992197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404514253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896468,0.003766212,0.00012368422,0.0019431878,0.00015236007,0.0033884305,0.00046010467,0.000033271594,0.00048593798],"genre_scores_gemma":[0.9968472,0.00052244787,0.0010784902,0.00053275144,0.000049066475,0.00046688633,0.00045356562,0.000026888607,0.00002270478],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9979544,0.000212501,0.0007625813,0.00070661487,0.00013095651,0.00023291624],"domain_scores_gemma":[0.9989392,0.00015998063,0.00026936256,0.00033068573,0.00014794248,0.0001528025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002135034,0.00022521926,0.0006751154,0.00035568365,0.00007667864,0.00019522458,0.00018275592,0.00007915234,0.00015479946],"category_scores_gemma":[0.00006768249,0.00021755318,0.0001572142,0.00031520065,0.000056046894,0.0002882044,0.00009176472,0.00016092516,0.000014455349],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005188836,0.0026096536,0.4505055,0.0019700176,0.005860148,0.000013043445,0.0077762497,0.23437858,0.0045751086,0.00014666423,0.0076718912,0.28397426],"study_design_scores_gemma":[0.004486073,0.00012659898,0.03616035,0.00018278856,0.0045475014,0.0000046148575,0.00016048511,0.92854285,0.025195384,0.00007514914,0.00030579607,0.00021242713],"about_ca_topic_score_codex":0.0016726798,"about_ca_topic_score_gemma":0.000793081,"teacher_disagreement_score":0.6941643,"about_ca_system_score_codex":0.00083301414,"about_ca_system_score_gemma":0.0012448282,"threshold_uncertainty_score":0.8871561},"labels":[],"label_agreement":null},{"id":"W4404905928","doi":"10.1007/s41669-024-00541-3","title":"Economic Evaluation of Total Knee Replacement Compared with Non-Surgical Management for Knee Osteoarthritis in India","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Total Knee Arthroplasty Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Indigenous Peoples' Health; Ministry of Health and Family Welfare","keywords":"Medicine; Osteoarthritis; Total knee replacement; Quality-adjusted life year; Economic evaluation; Physical therapy; Implant; Knee replacement; Arthroplasty; Cost effectiveness; Surgery","score_opus":0.027701895563404584,"score_gpt":0.35563596999736913,"score_spread":0.32793407443396455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404905928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701123,0.0003593469,0.00002777894,0.0005112265,0.0006667846,0.0054970775,0.00012681224,0.000030291112,0.022668373],"genre_scores_gemma":[0.9960174,0.000033170785,0.0013271592,0.00014795415,0.000115083254,0.0010169874,0.00013478103,0.000051200463,0.0011562968],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99834174,0.0000573817,0.000629864,0.0005202063,0.00015726713,0.00029355573],"domain_scores_gemma":[0.9992636,0.00014239755,0.00012612813,0.00030191714,0.00004161648,0.00012437173],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012992435,0.000218398,0.0005348027,0.00024949107,0.000044302964,0.00010834856,0.00013569824,0.000047124726,0.0011196465],"category_scores_gemma":[0.0000064119736,0.00021367393,0.00010681524,0.000085078915,0.00005817569,0.00038070924,0.00022008488,0.00015517391,0.00017128121],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033436015,0.0018315994,0.13015252,0.00361845,0.006004381,0.0006127111,0.005223928,0.04713957,0.0010598913,0.010867838,0.020440452,0.73961264],"study_design_scores_gemma":[0.21438761,0.008726817,0.18247989,0.0023000152,0.0031147266,0.0008193439,0.002630887,0.47113708,0.010050282,0.00071308494,0.10165772,0.0019825704],"about_ca_topic_score_codex":0.00007734265,"about_ca_topic_score_gemma":0.00009362063,"teacher_disagreement_score":0.73763007,"about_ca_system_score_codex":0.0006386435,"about_ca_system_score_gemma":0.00029532166,"threshold_uncertainty_score":0.99979347},"labels":[],"label_agreement":null},{"id":"W4405460373","doi":"10.1007/s41669-024-00537-z","title":"Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"F. Hoffmann-La Roche; Roche","keywords":"Resource (disambiguation); Management science; Psychological intervention; Health care; Health technology; Set (abstract data type); Risk analysis (engineering); Economic evaluation; Computer science; Intervention (counseling); Knowledge management; Process management; Environmental economics; Business; Medicine; Economics; Nursing; Microeconomics","score_opus":0.7165022102291071,"score_gpt":0.6053250367160649,"score_spread":0.11117717351304224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405460373","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14714457,0.095101744,0.010283774,0.6582909,0.0041089673,0.012238879,0.004044501,0.0005347593,0.0682519],"genre_scores_gemma":[0.85905737,0.004344511,0.049104,0.08446541,0.0007803363,0.0010894682,0.00024826464,0.0001561751,0.0007544819],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9907072,0.0016822758,0.0057227802,0.001265338,0.000058302034,0.0005640907],"domain_scores_gemma":[0.9925254,0.0050321333,0.0015879954,0.00046862866,0.000025274268,0.00036056442],"candidate_categories":["metaresearch","metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.050815392,0.00034210278,0.0015531837,0.00058186287,0.00036408025,0.0010751697,0.00047612464,0.00015511029,0.0037259453],"category_scores_gemma":[0.0021100813,0.0004490659,0.00012082744,0.0001676227,0.00025260853,0.001601497,0.0003931996,0.00046574158,0.0019515437],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016009439,0.00006125861,0.0043594493,0.0005381491,0.00013602969,0.0000068405757,0.0016312498,0.0026004654,0.0000081604785,0.9398504,0.04692439,0.0038675836],"study_design_scores_gemma":[0.0027622639,0.00013770626,0.0049976385,0.0006228124,0.000024070296,0.0001339806,0.0015644886,0.1897468,0.000023375322,0.5281447,0.27073738,0.0011047822],"about_ca_topic_score_codex":0.0020989024,"about_ca_topic_score_gemma":0.00069682155,"teacher_disagreement_score":0.71191275,"about_ca_system_score_codex":0.0016425247,"about_ca_system_score_gemma":0.0011370837,"threshold_uncertainty_score":0.9999618},"labels":[],"label_agreement":null},{"id":"W4408972758","doi":"10.1007/s41669-025-00567-1","title":"Cost-Effectiveness Analysis of Daridorexant for the Pharmacological Treatment of Chronic Insomnia Disorder in Adults","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Sleep and related disorders","field":"Psychology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Idorsia Pharmaceuticals","keywords":"Insomnia; Chronic insomnia; Medicine; Physical therapy; Psychiatry; Sleep disorder","score_opus":0.05065804717556651,"score_gpt":0.4323878008586311,"score_spread":0.3817297536830646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408972758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983252,0.0043874444,0.0008000682,0.0005381136,0.00091559073,0.0050459034,0.00025544304,0.000011077269,0.0047943853],"genre_scores_gemma":[0.9955571,0.0019404277,0.00002157076,0.00018408801,0.000022625334,0.0019910226,0.00006907738,0.000013260477,0.00020077784],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99859005,0.00019624397,0.0005255369,0.00038886492,0.000035663732,0.00026361903],"domain_scores_gemma":[0.9983254,0.001094762,0.00021623097,0.0002805204,0.000044671102,0.000038425012],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041395155,0.00018579607,0.0006298303,0.00032065902,0.00006908728,0.000017823602,0.00059854746,0.000108587956,0.0011198085],"category_scores_gemma":[0.000011738099,0.000130116,0.00027398395,0.00057711365,0.0001374392,0.00007208118,0.00012170984,0.0001033487,0.000010194516],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017216427,0.012426122,0.16526626,0.00017065353,0.070992805,0.000008482455,0.0046367943,0.11530099,0.0014977799,0.010520386,0.002363846,0.5995995],"study_design_scores_gemma":[0.14514616,0.0024136226,0.33547622,0.00017070222,0.031604838,0.000002168724,0.004048776,0.32677308,0.015871432,0.0011664504,0.1362214,0.0011051488],"about_ca_topic_score_codex":0.0030756085,"about_ca_topic_score_gemma":0.0008569277,"teacher_disagreement_score":0.5984943,"about_ca_system_score_codex":0.00025579927,"about_ca_system_score_gemma":0.00012379583,"threshold_uncertainty_score":0.9997933},"labels":[],"label_agreement":null},{"id":"W4409906719","doi":"10.1007/s41669-025-00579-x","title":"Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Work & Health","funders":"Faculty of Medicine Siriraj Hospital, Mahidol University; Thailand Science Research and Innovation; King Chulalongkorn Memorial Hospital","keywords":"Enzyme replacement therapy; Value (mathematics); Glucocerebrosidase; Disease; Value for money; Economics; Medicine; Psychology; Internal medicine; Public economics; Statistics; Mathematics","score_opus":0.07914948478163432,"score_gpt":0.44021923930942997,"score_spread":0.36106975452779566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409906719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808066,0.0017056221,0.00010633642,0.011030335,0.00014164505,0.002582009,0.00006344553,0.000008376519,0.0035556145],"genre_scores_gemma":[0.9925624,0.001194122,0.00012676745,0.004156011,0.000046424015,0.00031102492,0.000040601073,0.00002107645,0.0015415673],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990168,0.000085428444,0.00029665267,0.00029872995,0.00008279714,0.00021957584],"domain_scores_gemma":[0.9992259,0.0002553191,0.00008274263,0.00027532468,0.00005523405,0.00010547592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007017287,0.00012760474,0.00029493027,0.00009125399,0.000094516545,0.00014646845,0.00028602456,0.00003479201,0.00014197975],"category_scores_gemma":[0.00010592521,0.00009982311,0.000052138104,0.00009640936,0.00007209422,0.0001924505,0.00022218583,0.00014294006,0.0000011193648],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043147437,0.003802117,0.53148556,0.0027806468,0.0033673032,0.00009392919,0.008826824,0.004583043,0.11566465,0.01843507,0.08330905,0.18450439],"study_design_scores_gemma":[0.10908019,0.0010970661,0.23004583,0.0008911984,0.001080932,0.000014285502,0.0054741576,0.11627708,0.2534934,0.008905985,0.2720926,0.0015472914],"about_ca_topic_score_codex":0.0009781836,"about_ca_topic_score_gemma":0.0000614973,"teacher_disagreement_score":0.30143973,"about_ca_system_score_codex":0.00016464581,"about_ca_system_score_gemma":0.00046329878,"threshold_uncertainty_score":0.40706682},"labels":[],"label_agreement":null},{"id":"W4415481382","doi":"10.1007/s41669-025-00606-x","title":"The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Newcastle University","keywords":"Consistency (knowledge bases); Transferability; Nice; Economic evaluation; Value (mathematics); Key (lock)","score_opus":0.4556949474363551,"score_gpt":0.5296241747478914,"score_spread":0.07392922731153628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415481382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801983,0.0013055601,0.00092225015,0.0010820997,0.00029308087,0.0031222277,0.0129594505,0.0000035043565,0.000113530776],"genre_scores_gemma":[0.9978933,0.0005699881,0.00042509224,0.00020596724,0.00001775257,0.00061814795,0.00020916502,0.000013445944,0.00004714467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960427,0.00038809245,0.0027433368,0.00055323367,0.000045534238,0.00022709201],"domain_scores_gemma":[0.992294,0.005611634,0.0014169697,0.0004373046,0.00009527759,0.00014479655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006367959,0.00019832747,0.0014239709,0.00022194975,0.00023831234,0.00008243636,0.00038090756,0.00005961872,0.00006212961],"category_scores_gemma":[0.0004967284,0.0002176363,0.00015253715,0.00012756769,0.00017341759,0.0003491248,0.00010449792,0.00006983365,0.0000012524522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005311699,0.00013250591,0.9814475,0.0004017817,0.0045343623,5.0267563e-8,0.00030406532,0.0040503144,0.0000805897,0.00683545,0.0001757417,0.0015064706],"study_design_scores_gemma":[0.006371114,0.00005861219,0.910118,0.00011453407,0.0012710505,7.347119e-8,0.0003294167,0.07354306,0.0005264759,0.0064652395,0.00097285915,0.00022955344],"about_ca_topic_score_codex":0.41518173,"about_ca_topic_score_gemma":0.34257084,"teacher_disagreement_score":0.07261088,"about_ca_system_score_codex":0.0006464619,"about_ca_system_score_gemma":0.0008091832,"threshold_uncertainty_score":0.8874951},"labels":[],"label_agreement":null},{"id":"W4416015139","doi":"10.1007/s41669-025-00610-1","title":"Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; ABB (Canada); CancerCare Manitoba; University of Calgary","funders":"","keywords":"Venetoclax; Obinutuzumab; Ven; Chronic lymphocytic leukemia; Ibrutinib; Bendamustine; IGHV@; Cancer","score_opus":0.019483530240405847,"score_gpt":0.3295830902794832,"score_spread":0.31009956003907735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416015139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987792,0.00018420916,0.000016859281,0.00019307419,0.000051868174,0.0050909733,0.00006017741,0.000026054344,0.006584778],"genre_scores_gemma":[0.9971298,0.0001570731,0.000071850794,0.00068680174,0.00001536883,0.00059398205,0.0004774018,0.000038334885,0.00082938845],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9974029,0.00014453442,0.00060884136,0.00078914297,0.00021005467,0.00084449403],"domain_scores_gemma":[0.9984518,0.00015588531,0.00014848443,0.0006676297,0.00017707072,0.00039907853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006300865,0.00032686724,0.0008442981,0.0012323641,0.00009887179,0.00015474958,0.0006231207,0.00014591584,0.0005063772],"category_scores_gemma":[0.00005478848,0.0002965009,0.000072443305,0.0019600994,0.0001350482,0.00038443087,0.00021231498,0.00039907402,0.000050262654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010018899,0.0002738993,0.7677886,0.00070549356,0.00269251,0.00064763083,0.00081888406,0.2017238,0.000011593024,0.00021557708,0.0017733158,0.013329818],"study_design_scores_gemma":[0.112921245,0.00039671262,0.1857493,0.00034766935,0.00080053153,0.000012895404,0.00004723144,0.6959579,0.00035871175,0.00003995048,0.0029933418,0.00037451606],"about_ca_topic_score_codex":0.7030901,"about_ca_topic_score_gemma":0.76927114,"teacher_disagreement_score":0.5820393,"about_ca_system_score_codex":0.51788026,"about_ca_system_score_gemma":0.16819793,"threshold_uncertainty_score":0.99994874},"labels":[],"label_agreement":null},{"id":"W4416197305","doi":"10.1007/s41669-025-00613-y","title":"Cost of Chronic Heart Failure Among Adult Europeans—A Systematic Literature Review","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Systematic review; Heart failure; Protocol (science); MEDLINE; Medical literature","score_opus":0.021714652397324567,"score_gpt":0.3485529109715103,"score_spread":0.32683825857418575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416197305","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052830167,0.40675804,0.00063135405,0.2846059,0.0029031897,0.08936835,0.00031748446,0.00051682355,0.1620687],"genre_scores_gemma":[0.64815307,0.17145638,0.0072026127,0.08193905,0.0007535238,0.003981184,0.00090136594,0.00026412922,0.085348666],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985199,0.00013457017,0.0006755435,0.00034339007,0.000084291954,0.00024232383],"domain_scores_gemma":[0.99895585,0.000059738555,0.00018215504,0.0005372309,0.00013435917,0.00013064207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005491817,0.00023174883,0.0009389017,0.00013371889,0.000059358958,0.00009954003,0.00036455897,0.000045848596,0.0004525804],"category_scores_gemma":[0.000052622963,0.00018971616,0.00017982366,0.00025144796,0.000039656054,0.00028944705,0.0002959061,0.00019153752,0.00025369696],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000759575,0.00029349528,0.0025548746,0.21287386,0.0009775672,0.000049559858,0.00011767205,0.000013797824,0.00042587947,0.0017402582,0.7798079,0.0010691345],"study_design_scores_gemma":[0.0068959524,0.00023767154,0.0012450123,0.26719853,0.002898162,0.000044649143,0.00008729877,0.001201365,0.0035903894,0.000036964262,0.71613175,0.0004322489],"about_ca_topic_score_codex":0.000035592988,"about_ca_topic_score_gemma":0.00005040167,"teacher_disagreement_score":0.5953229,"about_ca_system_score_codex":0.00022226927,"about_ca_system_score_gemma":0.0001562003,"threshold_uncertainty_score":0.77364004},"labels":[],"label_agreement":null}]}